WO2020264499A1 - Irak degraders and uses thereof - Google Patents

Irak degraders and uses thereof Download PDF

Info

Publication number
WO2020264499A1
WO2020264499A1 PCT/US2020/040125 US2020040125W WO2020264499A1 WO 2020264499 A1 WO2020264499 A1 WO 2020264499A1 US 2020040125 W US2020040125 W US 2020040125W WO 2020264499 A1 WO2020264499 A1 WO 2020264499A1
Authority
WO
WIPO (PCT)
Prior art keywords
ring
nitrogen
sulfur
oxygen
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/040125
Other languages
English (en)
French (fr)
Inventor
Nello Mainolfi
Nan JI
Matthew M. Weiss
Xiaozhang Zheng
Yi Zhang
Paul R. FLEMING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kymera Therapeutics Inc
Original Assignee
Kymera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to PH1/2022/500002A priority Critical patent/PH12022500002A1/en
Priority to AU2020302118A priority patent/AU2020302118A1/en
Priority to MX2021015995A priority patent/MX2021015995A/es
Priority to BR112021026517A priority patent/BR112021026517A2/pt
Priority to KR1020227003218A priority patent/KR20220032063A/ko
Priority to CN202080059563.1A priority patent/CN114502158A/zh
Priority to CA3144805A priority patent/CA3144805A1/en
Priority to US17/597,165 priority patent/US12545659B2/en
Priority to JP2021577410A priority patent/JP7687970B2/ja
Priority to EP20833679.2A priority patent/EP3989966A4/en
Application filed by Kymera Therapeutics Inc filed Critical Kymera Therapeutics Inc
Publication of WO2020264499A1 publication Critical patent/WO2020264499A1/en
Priority to MX2024013970A priority patent/MX2024013970A/es
Priority to IL289267A priority patent/IL289267A/en
Priority to CONC2021/0017893A priority patent/CO2021017893A2/es
Anticipated expiration legal-status Critical
Priority to US18/315,267 priority patent/US20240059674A1/en
Priority to JP2025085728A priority patent/JP2025113407A/ja
Priority to US19/356,388 priority patent/US20260042749A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Definitions

  • the present invention relates to compounds and methods useful for the modulation of one or more interleukin-1 receptor-associated kinases (“IRAK”) via ubiquitination and/or degradation by compounds according to the present invention.
  • IRAK interleukin-1 receptor-associated kinases
  • the invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
  • Ubiquitin-Proteasome Pathway is a critical pathway that regulates key regulator proteins and degrades misfolded or abnormal proteins. UPP is central to multiple cellular processes, and if defective or imbalanced, it leads to pathogenesis of a variety of diseases. The covalent attachment of ubiquitin to specific protein substrates is achieved through the action of E3 ubiquitin ligases.
  • E3 ubiquitin ligases which facilitate the ubiquitination of different proteins in vivo, which can be divided into four families: HECT-domain E3s, U-box E3s, monomeric RING E3s and multi-subunit E3s. See generally Li et al. (PLOS One, 2008, 3, 1487) titled“Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle’s dynamics and signaling.”; Berndsen et al. (Nat. Struct. Mol.
  • UPP plays a key role in the degradation of short-lived and regulatory proteins important in a variety of basic cellular processes, including regulation of the cell cycle, modulation of cell surface receptors and ion channels, and antigen presentation.
  • the pathway has been implicated in several forms of malignancy, in the pathogenesis of several genetic diseases (including cystic fibrosis, Angelman’s syndrome, and Liddle syndrome), in immune surveillance/viral pathogenesis, and in the pathology of muscle wasting.
  • Many diseases are associated with an abnormal UPP and negatively affect cell cycle and division, the cellular response to stress and to extracellular modulators, morphogenesis of neuronal networks, modulation of cell surface receptors, ion channels, the secretory pathway, DNA repair and biogenesis of organelles.
  • the UPP is used to induce selective protein degradation, including use of fusion proteins to artificially ubiquitinate target proteins and synthetic small-molecule probes to induce proteasome-dependent degradation.
  • Bifunctional compounds composed of a target protein- binding ligand and an E3 ubiquitin ligase ligand, induced proteasome-mediated degradation of selected proteins via their recruitment to E3 ubiquitin ligase and subsequent ubiquitination. These drug-like molecules offer the possibility of temporal control over protein expression.
  • Such compounds are capable of inducing the inactivation of a protein of interest upon addition to cells or administration to an animal or human, and could be useful as biochemical reagents and lead to a new paradigm for the treatment of diseases by removing pathogenic or oncogenic proteins (Crews C, Chemistry & Biology, 2010, 17(6):551-555; Schnnekloth JS Jr., Chembiochem, 2005, 6(l):40-46).
  • the present application relates novel bifunctional compounds, which function to recruit IRAK kinases to E3 Ubiquitin Ligase for degradation, and methods of preparation and uses thereof.
  • the present disclosure provides bifunctional compounds, which find utility as modulators of targeted ubiquitination of IRAK kinases, which are then degraded and/or otherwise inhibited by the bifunctional compounds as described herein.
  • monovalent compounds which find utility as inducers of targeted ubiquitination of IRAK kinases, which are then degraded and/or otherwise inhibited by the monovalent compounds as described herein.
  • An advantage of the compounds provided herein is that a broad range of pharmacological activities is possible, consistent with the degradation/inhibition of IRAK kinases.
  • the description provides methods of using an effective amount of the compounds as described herein for the treatment or amelioration of a disease condition, such as cancer, e.g., multiple myeloma.
  • the present application further relates to targeted degradation of IRAK kinases through the use of bifunctional molecules, including bifunctional molecules that link a degradation inducing moiety to a ligand that binds IRAK kinases having the following general formula I:
  • Compounds of the present invention are useful for treating a variety of diseases, disorders or conditions, associated with regulation of signaling pathways implicating IRAK kinases. Such diseases, disorders, or conditions include those described herein.
  • Compounds provided by this invention are also useful for the study of IRAK enzymes in biological and pathological phenomena; the study of intracellular signal transduction pathways occurring in bodily tissues; and the comparative evaluation of new IRAK inhibitors or IRAK degraders or other regulators of kinases, signaling pathways, and cytokine levels in vitro or in vivo.
  • IRAK enzymes in biological and pathological phenomena
  • the study of intracellular signal transduction pathways occurring in bodily tissues and the comparative evaluation of new IRAK inhibitors or IRAK degraders or other regulators of kinases, signaling pathways, and cytokine levels in vitro or in vivo.
  • Compounds of the present invention, and compositions thereof, are useful as degraders and/or inhibitors of one or more IRAK protein kinases.
  • a provided compound degrades and/or inhibits IRAK-1/2/3/4.
  • the present invention provides a compound of formula I:
  • IRAK is an IRAK binding moiety capable of binding to one or more of IRAK-1, -2, -3, or -4; L is a bivalent moiety that connects IRAK to DIM; and
  • DIM is a degradation inducing moiety.
  • aliphatic or“aliphatic group”, as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as "carbocycle,”“cycloaliphatic” or“cycloalkyl”), that has a single point of attachment to the rest of the molecule.
  • aliphatic groups contain 1-6 aliphatic carbon atoms.
  • aliphatic groups contain 1-5 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms.
  • “cycloaliphatic” (or“carbocycle” or“cycloalkyl”) refers to a monocyclic C 3 -C 6 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule.
  • Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
  • bridged bicyclic refers to any bicyclic ring system, i.e. carbocyclic or heterocyclic, saturated or partially unsaturated, having at least one bridge.
  • a“bridge” is an unbranched chain of atoms or an atom or a valence bond connecting two bridgeheads, where a“bridgehead” is any skeletal atom of the ring system which is bonded to three or more skeletal atoms (excluding hydrogen).
  • a bridged bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • bridged bicyclic groups are well known in the art and include those groups set forth below where each group is attached to the rest of the molecule at any substitutable carbon or nitrogen atom. Unless otherwise specified, a bridged bicyclic group is optionally substituted with one or more substituents as set forth for aliphatic groups. Additionally or alternatively, any substitutable nitrogen of a bridged bicyclic group is optionally substituted. Exemplary bridged bicyclics include:
  • lower alkyl refers to a C1-4 straight or branched alkyl group.
  • exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.
  • lower haloalkyl refers to a C1-4 straight or branched alkyl group that is substituted with one or more halogen atoms.
  • heteroatom means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl) or NR + (as in N-substituted pyrrolidinyl)).
  • bivalent C1-8 (or C1-6) saturated or unsaturated, straight or branched, hydrocarbon chain refers to bivalent alkylene, alkenylene, and alkynylene chains that are straight or branched as defined herein.
  • alkylene refers to a bivalent alkyl group.
  • An“alkylene chain” is a polymethylene group, i.e.,–(CH 2 )n–, wherein n is a positive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3.
  • a substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
  • alkenylene refers to a bivalent alkenyl group.
  • a substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
  • cyclopropylenyl refers to a bivalent cyclopropyl group of the following structure: .
  • halogen means F, Cl, Br, or I.
  • aryl used alone or as part of a larger moiety as in“aralkyl,”“aralkoxy,” or “aryloxyalkyl,” refers to monocyclic or bicyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members.
  • the term“aryl” may be used interchangeably with the term“aryl ring.”
  • “aryl” refers to an aromatic ring system which includes, but not limited to, phenyl, biphenyl, naphthyl, anthracyl and the like, which may bear one or more substituents.
  • aryl is a group in which an aromatic ring is fused to one or more non–aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like.
  • heteroaryl and“heteroar—,” used alone or as part of a larger moiety e.g., “heteroaralkyl,” or“heteroaralkoxy,” refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 p electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms.
  • heteroatom refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen.
  • Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl.
  • heteroaryl and“heteroar—”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring.
  • Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H–quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3–b]–1,4–oxazin–3(4H)–one.
  • a heteroaryl group may be mono– or bicyclic.
  • the term“heteroaryl” may be used interchangeably with the terms“heteroaryl ring,”“heteroaryl group,” or“heteroaromatic,” any of which terms include rings that are optionally substituted.
  • the term“heteroaralkyl” refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.
  • heterocycle As used herein, the terms“heterocycle,”“heterocyclyl,”“heterocyclic radical,” and “heterocyclic ring” are used interchangeably and refer to a stable 5– to 7–membered monocyclic or 7–10–membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above.
  • nitrogen includes a substituted nitrogen.
  • the nitrogen may be N (as in 3,4–dihydro– 2H–pyrrolyl), NH (as in pyrrolidinyl), or + NR (as in N–substituted pyrrolidinyl).
  • a heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted.
  • saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothiophenyl pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, and quinuclidinyl.
  • heterocycle “heterocyclyl,”“heterocyclyl ring,”“heterocyclic group,”“heterocyclic moiety,” and“heterocyclic radical,” are used interchangeably herein, and also include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl, or cycloaliphatic rings, such as indolinyl, 3H–indolyl, chromanyl, phenanthridinyl, or tetrahydroquinolinyl.
  • a heterocyclyl group may be mono– or bicyclic.
  • the term“heterocyclylalkyl” refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.
  • the term“partially unsaturated” refers to a ring moiety that includes at least one double or triple bond.
  • the term“partially unsaturated” is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.
  • compounds of the invention may contain“optionally substituted” moieties.
  • the term“substituted,” whether preceded by the term“optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent.
  • an“optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.
  • Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds.
  • the term“stable,” as used herein, refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
  • Suitable monovalent substituents on R° are independently halogen,–(CH 2 ) 0–2 R ⁇ , –(haloR ⁇ ),–(CH 2 )0–2OH,–(CH 2 )0–2OR ⁇ ,–(CH 2 )0–2CH(OR ⁇ ) 2 ; -O(haloR ⁇ ),–CN,–N3,–(CH 2 )0– 2 C(O)R ⁇ ,–(CH 2 ) 0–2 C(O)OH,–(CH 2 ) 0–2 C(O)OR ⁇ ,–(CH 2 ) 0–2 SR ⁇ ,–(CH 2 ) 0–2 SH,–(CH 2 ) 0–2 NH 2 ,– (CH 2 ) 0–2 NHR ⁇ ,–(CH 2 ) 0–2 NR
  • Suitable divalent substituents that are bound to vicinal substitutable carbons of an“optionally substituted” group include:–O(CR * 2 ) 2– 3O–, wherein each independent occurrence of R * is selected from hydrogen, C1–6 aliphatic which may be substituted as defined below, or an unsubstituted 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Suitable substituents on the aliphatic group of R * include halogen,–R ⁇ , -(haloR ⁇ ), -OH, –OR ⁇ ,–O(haloR ⁇ ),–CN,–C(O)OH,–C(O)OR ⁇ ,–NH2,–NHR ⁇ ,–NR ⁇ 2, or–NO 2 , wherein each R ⁇ is unsubstituted or where preceded by“halo” is substituted only with one or more halogens, and is independently C1–4 aliphatic,–CH 2 Ph,–O(CH 2 )0–1Ph, or a 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Suitable substituents on a substitutable nitrogen of an“optionally substituted” group include –R ⁇ , –NR ⁇ 2, –C(O)R ⁇ , –C(O)OR ⁇ , –C(O)C(O)R ⁇ , – C(O)CH 2 C(O)R ⁇ , -S(O) 2 R ⁇ , -S(O) 2 NR ⁇ 2 ,–C(S)NR ⁇ 2 ,–C(NH)NR ⁇ 2 , or–N(R ⁇ )S(O) 2 R ⁇ ; wherein each R ⁇ is independently hydrogen, C 1–6 aliphatic which may be substituted as defined below, unsubstituted–OPh, or an unsubstituted 5–6–membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrence
  • Suitable substituents on the aliphatic group of R ⁇ are independently halogen,– R ⁇ , -(haloR ⁇ ),–OH,–OR ⁇ ,–O(haloR ⁇ ),–CN,–C(O)OH,–C(O)OR ⁇ ,–NH2,–NHR ⁇ ,–NR ⁇ 2, or -NO 2 , wherein each R ⁇ is unsubstituted or where preceded by“halo” is substituted only with one or more halogens, and is independently C 1–4 aliphatic,–CH 2 Ph,–O(CH 2 ) 0–1 Ph, or a 5–6– membered saturated, partially unsaturated, or aryl ring having 0–4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • the term“provided compound” refers to any genus, subgenus, and/or species set forth herein.
  • pharmaceutically acceptable salt refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1–19, incorporated herein by reference.
  • Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases.
  • suitable inorganic and organic acids and bases include those derived from suitable inorganic and organic acids and bases.
  • pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2– hydroxy–ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2–naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pec
  • Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C1–4alkyl)4 salts.
  • Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
  • Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
  • structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention.
  • structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
  • compounds having the present structures including the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
  • Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present invention
  • an inhibitor is defined as a compound that binds to and/or inhibits an IRAK kinase with measurable affinity.
  • an inhibitor has an IC 50 and/or binding constant of less than about 50 ⁇ M, less than about 1 ⁇ M, less than about 500 nM, less than about 100 nM, less than about 10 nM, or less than about 1 nM.
  • the term“degrader” is defined as a heterobifunctional or monovalent compound that binds to and/or inhibits both an IRAK kinase and an E3 ligase with measurable affinity resulting in the ubiqitination and subsequent degradation of the IRAK kinase.
  • a degrader has an DC 50 of less than about 50 ⁇ M, less than about 1 ⁇ M, less than about 500 nM, less than about 100 nM, less than about 10 nM, or less than about 1 nM.
  • the term“monovalent” refers to a degrader compound without an appended E3 ligase binding moiety.
  • a compound of the present invention may be tethered to a detectable moiety. It will be appreciated that such compounds are useful as imaging agents.
  • a detectable moiety may be attached to a provided compound via a suitable substituent.
  • suitable substituent refers to a moiety that is capable of covalent attachment to a detectable moiety.
  • moieties are well known to one of ordinary skill in the art and include groups containing, e.g., a carboxylate moiety, an amino moiety, a thiol moiety, or a hydroxyl moiety, to name but a few.
  • moieties may be directly attached to a provided compound or via a tethering group, such as a bivalent saturated or unsaturated hydrocarbon chain.
  • such moieties may be attached via click chemistry.
  • such moieties may be attached via a 1,3-cycloaddition of an azide with an alkyne, optionally in the presence of a copper catalyst.
  • Methods of using click chemistry are known in the art and include those described by Rostovtsev et al., Angew. Chem. Int. Ed.2002, 41, 2596-99 and Sun et al., Bioconjugate Chem., 2006, 17, 52-57.
  • the term“detectable moiety” is used interchangeably with the term "label” and relates to any moiety capable of being detected, e.g., primary labels and secondary labels.
  • Primary labels such as radioisotopes (e.g., tritium, 32 P, 33 P, 35 S, or 14 C), mass-tags, and fluorescent labels are signal generating reporter groups which can be detected without further modifications.
  • Detectable moieties also include luminescent and phosphorescent groups.
  • secondary label refers to moieties such as biotin and various protein antigens that require the presence of a second intermediate for production of a detectable signal.
  • the secondary intermediate may include streptavidin-enzyme conjugates.
  • antigen labels secondary intermediates may include antibody-enzyme conjugates.
  • fluorescent label refers to moieties that absorb light energy at a defined excitation wavelength and emit light energy at a different wavelength.
  • fluorescent labels include, but are not limited to: Alexa Fluor dyes (Alexa Fluor 350, Alexa Fluor 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 660 and Alexa Fluor 680), AMCA, AMCA-S, BODIPY dyes (BODIPY FL, BODIPY R6G, BODIPY TMR, BODIPY TR, BODIPY 530/550, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY 630/650, BODIPY 650/665), Carboxyrhodamine 6G, carboxy
  • mass-tag refers to any moiety that is capable of being uniquely detected by virtue of its mass using mass spectrometry (MS) detection techniques.
  • mass-tags include electrophore release tags such as N-[3-[4’-[(p- Methoxytetrafluorobenzyl)oxy]phenyl]-3-methylglyceronyl]isonipecotic Acid, 4’-[2,3,5,6- Tetrafluoro-4-(pentafluorophenoxyl)]methyl acetophenone, and their derivatives.
  • mass-tags include, but are not limited to, nucleotides, dideoxynucleotides, oligonucleotides of varying length and base composition, oligopeptides, oligosaccharides, and other synthetic polymers of varying length and monomer composition.
  • nucleotides dideoxynucleotides
  • oligonucleotides of varying length and base composition oligopeptides, oligosaccharides
  • other synthetic polymers of varying length and monomer composition.
  • a large variety of organic molecules, both neutral and charged (biomolecules or synthetic compounds) of an appropriate mass range (100-2000 Daltons) may also be used as mass-tags.
  • measurable affinity and“measurably inhibit,” as used herein, means a measurable change in an IRAK protein kinase activity between a sample comprising a compound of the present invention, or composition thereof, and an IRAK protein kinase, and an equivalent sample comprising an IRAK protein kinase, in the absence of said compound, or composition thereof.
  • the present invention provides a compound of formula I:
  • IRAK is an IRAK binding moiety capable of binding to one or more of IRAK-1, -2, -3, or -4; L is a bivalent moiety that connects IRAK to DIM; and
  • DIM is a degradation inducing moiety.
  • the present invention provides a compound of formula I:
  • IRAK is an IRAK-4 binding moiety
  • L is a bivalent moiety that connects IRAK to DIM
  • DIM is LBM, a lysine mimetic, or a hydrogen atom.
  • IRAK Binding Moiety IRAK
  • the present invention provides a compound of formula I, where IRAK is a IRAK-4 binding moiety thereby forming a compound of formulae I-a or I-b:
  • each R x is independently hydrogen, deuterium, R z , halogen, -CN, -NO 2 , -OR, - SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2, -S(O)R, -CF 2 R, -CF 3 , -CR 2 (OR), - CR 2 (NR 2 ), -C(O)R, -C(O)OR, -C(O)NR 2 , - C(S)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , -N(R)S(O) 2 R, -N + (O-)R 2 , -OP(O)R 2 , -N + (O-)R 2 ,
  • R x groups are optionally taken together to form an optionally substituted 5-6 membered partially unsaturated or aryl fused ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
  • each R is independently hydrogen, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • two R groups on the same carbon or nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the carbon or nitrogen, independently selected from nitrogen, oxygen, and sulfur;
  • each R y is independently hydrogen, deuterium, R z , halogen, -CN, -NO 2 , -OR, - SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2 , -S(O)R, -CF2R, -CF 3 , -CR 2 (OR), - CR 2 (NR 2 ), -C(O)R, -C(O)OR, -C(O)NR 2 , - C(S)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , -N(R)S(O) 2 R, -OP(O)R 2 , -OP(O)(OR) 2 , -OP(O)(OR) 2
  • each R z is independently an optionally substituted group selected from C 1-6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • Ring P and Ring Q are optionally fused rings independently selected from phenyl or benzo, a 4-7 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring P and Ring Q are independently and optionally substituted with 1-2 oxo groups;
  • Ring T is selected from phenyl, a 4-7 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring T is further optionally substituted with 1-2 oxo groups;
  • -Cy x - is an optionally substituted ring selected from a 3-5 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein -Cy x - is optionally substituted with 1-2 oxo groups;
  • X is a covalent bond or a 4-6 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • each x is 0, 1, 2, 3 or 4;
  • each y is 0, 1, 2, 3 or 4.
  • the present invention provides a compound of formula I, where IRAK is a IRAK-4 binding moiety thereby forming a compound of formulae I ⁇ -a or I ⁇ -b:
  • each R x is independently hydrogen, deuterium, R z , halogen, -CN, -NO 2 , -OR, - SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2, -S(O)R, -CFR 2 , -CF 2 R, -CF 3 , -CR 2 (OR), - CR 2 (NR 2 ), -C(O)R, -C(O)OR, -C(O)NR 2 , - C(S)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , -N(R)S(O) 2 R, -N + (O-)R 2 , -OP(O)R 2 , -N + (O
  • R x groups are optionally taken together to form an optionally substituted 5-6 membered partially unsaturated or aryl fused ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 3-5 membered saturated or partially unsaturated carbocyclic or heterocyclic spiro fused ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur,
  • each R is independently hydrogen, or an optionally substituted group selected from C 1-6 aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • two R groups on the same atom are optionally taken together with their intervening atoms to form a 4-11 membered saturated or partially unsaturated carbocyclic or heterocyclic monocyclic, bicyclic, bridged bicyclic, spiro, or heteroaryl ring having 0-3 heteroatoms, in addition to the atom to which they are attached, independently selected from nitrogen, oxygen, and sulfur;
  • each R y is independently hydrogen, deuterium, R z , halogen, -CN, -NO 2 , -OR, - SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2, -S(O)R, -CFR 2 , -CF 2 R, -CF 3 , -CR 2 (OR), - CR 2 (NR 2 ), -C(O)R, -C(O)OR, -C(O)NR 2 , - C(S)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , -N(R)S(O) 2 R, -OP(O)R 2 , -OP(O)(OR) 2 , -OP(O)
  • each R z is independently an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • Ring P and Ring Q are optionally fused rings independently selected from phenyl or benzo, a 4-7 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring P and Ring Q are independently and optionally substituted with 1-2 oxo groups;
  • Ring T is selected from phenyl, a 4-7 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-9 membered mono- or bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring T is further optionally substituted with 1-2 oxo groups;
  • -Cy x - is an optionally substituted ring selected from a 3-5 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein -Cy x - is optionally substituted with 1-2 oxo groups;
  • X is a covalent bond or a 4-6 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • each x is 0, 1, 2, 3 or 4;
  • each y is 0, 1, 2, 3 or 4.
  • the present invention provides a compound of formula I, where IRAK is a IRAK-4 binding moiety thereby forming a compound of formulae I ⁇ -a or I ⁇ -b:
  • each R x is independently hydrogen, deuterium, R z , halogen, -CN, -NO 2 , -OR, - SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2 , -S(O)R, -CFR 2 , -CF2R, -CF 3 , -CR 2 (OR), - CR 2 (NR 2 ), -C(O)R, -C(O)OR, -C(O)NR 2 , - C(S)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , -N(R)S(O) 2 R, -N + (O-)R 2 , -OP(O)R 2 , - OP
  • each R is independently hydrogen, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • two R groups on the same atom are optionally taken together with their intervening atoms to form a 4-11 membered saturated or partially unsaturated carbocyclic or heterocyclic monocyclic, bicyclic, bridged bicyclic, spiro, or heteroaryl ring having 0-3 heteroatoms, in addition to the atom to which they are attached, independently selected from nitrogen, oxygen, and sulfur;
  • each R y is independently hydrogen, deuterium, R z , halogen, -CN, -NO 2 , -OR, - SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2, -S(O)R, -CFR 2 , -CF 2 R, -CF 3 , -CR 2 (OR), - CR 2 (NR 2 ), -C(O)R, -C(O)OR, -C(O)NR 2 , - C(S)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , -N(R)S(O) 2 R, -OP(O)R 2 , -OP(O)(OR) 2 , -OP(O)
  • a single R y and a single R x are optionally taken together with their intervening atoms to form a 8-20 membered saturated or partially unsaturated carbocyclic or heterocyclic monocyclic or bicyclic ring having 1-10 heteroatoms, independently selected from nitrogen, oxygen, and sulfur;
  • each R z is independently an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4- 9 membered saturated or partially unsaturated carbocyclic or heterocyclic monocyclic, bicyclic, bridged bicyclic, or spirocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1- 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • Ring P and Ring Q are optionally fused rings independently selected from phenyl or benzo, a 4-7 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring P and Ring Q are independently and optionally substituted with 1-2 oxo groups;
  • Ring T is selected from phenyl, a 4-7 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-9 membered mono- or bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring T is further optionally substituted with 1-2 oxo groups;
  • -Cy x - is an optionally substituted ring selected from a 3-5 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein -Cy x - is optionally substituted with 1-2 oxo groups;
  • X is a covalent bond or a 4-6 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • each x is 0, 1, 2, 3 or 4; and each y is 0, 1, 2, 3 or 4.
  • a core structure depicted as includes for
  • each R x is independently hydrogen, deuterium, R z , halogen, -CN, -NO 2 , -OR, -SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2, -S(O)R, -CFR 2 , -CF 2 R, -CF 3 , - CR 2 (OR), -CR 2 (NR 2 ), -C(O)R, -C(O)OR, -C(O)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , -N(R)S(O) 2 R, -N + (O-)R 2 , -OP(O)R 2 , -OP(O)(OR)
  • each R x is independently hydrogen. In some embodiments, R x is deuterium. In some embodiments, each R x is independently R z . In some embodiments, each R x is independently halogen. In some embodiments, each R x is independently–CN. In some embodiments, each R x is independently -NO 2 . In some embodiments, each R x is independently– OR. In some embodiments, each R x is independently–SR. In some embodiments, each R x is independently -NR 2 . In some embodiments, each R x is independently -S(O) 2 R. In some embodiments, each R x is independently -S(O) 2 NR 2 .
  • each R x is independently -S(O)R. In some embodiments, each R x is independently -CFR 2 . In some embodiments, each R x is independently -CF 2 R. In some embodiments, each R x is independently - CF 3 . In some embodiments, each R x is independently -CR 2 (OR). In some embodiments, each R x is independently -CR 2 (NR 2 ). In some embodiments, each R x is independently -C(O)R. In some embodiments, each R x is independently -C(O)OR. In some embodiments, each R x is independently -C(O)NR 2 . In some embodiments, each R x is independently -N + (O-)R 2 .
  • each R x is independently -OP(O)R 2 . In some embodiments, each R x is independently -OP(O)(OR) 2 . In some embodiments, each R x is independently -OP(O)(OR)NR 2 . In some embodiments, each R x is independently -OP(O)(NR 2 ) 2 . In some embodiments each R x is independently -P(O)R 2 . In some embodiments, each R x is independently -SiR3. In some embodiments, each R x is independently -Si(OR)R 2 . In some embodiments, each R x is
  • each R x is independently In some embodiments,
  • two R x groups are optionally taken together to form an optionally substituted 5-6 membered partially unsaturated or aryl fused ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, two R x groups are optionally taken together to form an optionally substituted 3-5 membered saturated or partially unsaturated carbocyclic or heterocyclic spiro fused ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur, [0060] In some embodiments, R x is In some embodiments, R x is fluoro. In some embodiments, R x is -CF 2 H. In some embodiments, R x is -OMe. In some embodiments, R x is - SMe.
  • R x is -Me. In some embodiments, R x is -OCF 2 H. In some embodiments, R x is -OCF 3 . In some embodiments, R x is -S(O) 2 Me. In some embodiments, R x is In some embodiments, R x is In some embodiments, R x is . In some embodiments, R x is . In some embodiments, R x is In some embodiments, R x is In some embodiments, R x is In some embodiments, R x is In some embodiments, R x is In some embodiments, R x is In some embodiments, R x is . In some embodiments, R x is -OEt. In some embodiments, R x is -OiPr.
  • R x is In some embodiments, R x is In some embodiments, R x is . In some embodiments, R x is . In some embodiments, R x is . In some embodiments, R x is . In some embodiments, R x is . In some embodiments, R x is . In some embodiments,
  • each R x is selected from those depicted in Table 1, below.
  • each R is independently hydrogen, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or two R groups on the same atom are optionally taken together with their intervening atom to form a 4-11 membered saturated or partially unsaturated carbocyclic or heterocyclic monocyclic, bicyclic, bridged bicyclic, spiro, or heteroaryl ring having 0-3 heteroatoms, in addition to the atom to which they are attached, independently selected from nitrogen, oxygen, and sulfur.
  • each R is independently hydrogen. In some embodiments, each R is an optionally substituted group selected from C 1-6 aliphatic. In some embodiments, each R is an optionally substituted phenyl. In some embodiments, each R is an optionally substituted 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each R is an optionally substituted 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • two R groups on the same atom are optionally taken together with their intervening atom to form a 4-11 membered saturated or partially unsaturated carbocyclic or heterocyclic monocyclic, bicyclic, bridged bicyclic, spiro, or heteroaryl ring having 0-3 heteroatoms, in addition to the atom to which they are attached, independently selected from nitrogen, oxygen, and sulfur.
  • each R is selected from those depicted in Table 1, below.
  • each R y is independently hydrogen, deuterium, R z , halogen, -CN, -NO 2 , -OR, -SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2, -S(O)R, -CFR 2 , -CF 2 R, -CF 3 , - CR 2 (OR), -CR 2 (NR 2 ), -C(O)R, -C(O)OR, -C(O)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , -N(R)S(O) 2 R, -N + (O-)R 2 , -OP(O)R 2 , -OP(O)(OR)
  • R y groups are optionally taken together to form an optionally substituted 5-6 membered partially unsaturated or aryl fused ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; ; or a single R y and a single R x are optionally taken together with their intervening atoms to form a 8-20 membered saturated or partially unsaturated carbocyclic or heterocyclic monocyclic or bicyclic ring having 1-10 heteroatoms, independently selected from nitrogen, oxygen, and sulfur.
  • each R y is independently hydrogen. In some embodiments, R y is deuterium. In some embodiments, each R y is independently R z . In some embodiments, each R y is independently halogen. In some embodiments, each R y is independently–CN. In some embodiments, each R y is independently -NO 2 . In some embodiments, each R y is independently– OR. In some embodiments, each R y is independently–SR. In some embodiments, each R y is independently -NR 2 . In some embodiments, each R y is independently -S(O) 2 R. In some embodiments, each R y is independently -S(O) 2 NR 2 .
  • each R y is independently -S(O)R. In some embodiments, each R y is independently -CFR 2 . In some embodiments, each R y is independently -CF 2 R. In some embodiments, each R x is independently - CF 3 . In some embodiments, each R y is independently -CR 2 (OR). In some embodiments, each R y is independently -CR 2 (NR 2 ). In some embodiments, each R y is independently -C(O)R. In some embodiments, each R y is independently -C(O)OR. In some embodiments, each R y is independently -C(O)NR 2 . In some embodiments, each R y is independently -N + (O-)R 2 .
  • each R y is independently -OP(O)R 2 . In some embodiments, each R y is independently -OP(O)(OR) 2 . In some embodiments, each R y is independently -OP(O)(OR)NR 2 . In some embodiments, each R y is independently -OP(O)(NR 2 ) 2 . In some embodiments each R y is independently -P(O)R 2 . In some embodiments, each R y is independently -SiR3. In some embodiments, each R y is independently -Si(OR)R 2 . In some embodiments, each R y is
  • each R y is independently -SF 5 .
  • each R y is independently
  • two R y groups are optionally taken together to form an optionally substituted 5-6 membered partially unsaturated or aryl fused ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • a single R y and a single R x are optionally taken together with their intervening atoms to form a 8-20 membered saturated or partially unsaturated carbocyclic or heterocyclic monocyclic or bicyclic ring having 1-10 heteroatoms, independently selected from nitrogen, oxygen, and sulfur.
  • R y is fluoro. In some embodiments, R y is chloro. In some embodiments, R y is -CN. In some embodiments, R y is -CF 2 Me. In some embodiments, R y is - CFMe 2 . In some embodiments, R y is -Me. In some embodiments, R y is -OCF 3 . In some embodiments, R y is fluoro. In some embodiments, R y is cyclopropyl. In some embodiments, R y is In some embodiments, R y is
  • R y and R x taken together is . In some embodiments, R y and R x taken together i some embodiments, R y and R x taken together is . In some embodiments, R y and R x taken together is . In some embodiments, R y and R x taken together is . In some embodiments, R y and R x taken together is
  • each R y is selected from those depicted in Table 1, below.
  • each R z is independently an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4-9 membered saturated or partially unsaturated carbocyclic or heterocyclic monocyclic, bicyclic, bridged bicyclic, or spirocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • each R z is independently an optionally substituted group selected from C 1-6 aliphatic. In some embodiments, each R z is independently an optionally substituted phenyl. In some embodiments, each R z is independently an optionally substituted 4-9 membered saturated or partially unsaturated carbocyclic or heterocyclic monocyclic, bicyclic, bridged bicyclic, or spirocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, each R z is independently an optionally substituted 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • each R z is selected from those depicted in Table 1, below.
  • Ring P and Ring Q are optionally fused rings independently selected from phenyl or benzo, a 4-7 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring P and Ring Q are independently and optionally substituted with 1-2 oxo groups.
  • Ring P and Ring Q are independently phenyl or benzo. In some embodiments, Ring P and Ring Q are independently a 4-7 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring P and Ring Q are independently a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring P and Ring Q are independently and optionally substituted with 1-2 oxo groups.
  • Ring P and Ring Q are . In some embodiments, Ring P and Ring Q are .
  • Ring P and Ring Q are . In some embodiments, Ring P and Ring Q are .
  • Ring Q are .
  • Ring P and Ring Q are
  • Ring P and Ring Q are
  • Ring P and Ring Q are In some embodiments, Ring P and Ring Q are
  • Ring P and Ring Q are independently polar in some embodiments.
  • Ring P and Ring Q are independently polar in some embodiments.
  • Ring P and Ring Q are independently polar in some embodiments.
  • Ring P and Ring Q are independently polar in some embodiments.
  • Ring P and Ring Q are independently polar in some embodiments.
  • Ring P and Ring Q are selected from those depicted in Table 1, below.
  • Ring T is selected from phenyl, a 4-7 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-9 membered mono- or bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring T is further optionally substituted with 1-2 oxo groups.
  • Ring T is from phenyl.
  • Ring T is a 4-7 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • Ring T is a 5-9 membered mono- or bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, Ring T is further optionally substituted with 1-2 oxo groups.
  • Ring T is . In some embodiments, Ring T is
  • Ring T is . In some embodiments,
  • Ring T is . In some embodiments, Ring T is . In some
  • Ring T is . In some embodiments, Ring T is phenyl. In some
  • Ring T is . In some embodiments, Ring T is . In
  • Ring T is . In some embodiments, Ring T is . In some embodiments, Ring T is . In some embodiments, Ring T is . In some embodiments, Ring T is
  • Ring T is . In some embodiments, Ring T is . In some embodiments, Ring T is . In some embodiments, Ring T is . In some embodiments,
  • Ring T is . [0080] In some embodiments, Ring T is selected from those depicted in Table 1, below.
  • L x is a covalent bond.
  • Ring L x is -C(O)N(H)-. In some embodiments, Ring L x is -
  • L x combines with R y to form .
  • L x combines with Ry to form .
  • Ring L x is selected from those depicted in Table 1, below.
  • -Cy x - is an optionally substituted ring selected from a 3-5 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein - Cy x - is optionally substituted with 1-2 oxo groups.
  • -Cy x - is an optionally substituted ring selected from a 3-5 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • - Cy x - is a 5 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • -Cy x - is optionally substituted with 1-2 oxo groups.
  • Ring -Cy x - is selected from those depicted in Table 1, below.
  • X is a covalent bond or a 4-6 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
  • X is a covalent bond. In some embodiments, X is a 4-6 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. [0008] In some embodiments, X is . In some embodiments, X is .
  • X is selected from those depicted in Table 1, below.
  • Ring is selected from those depicted in Table 1, below.
  • each x and y are independently 0, 1, 2, 3 or 4.
  • each x and y are independently 0. In some embodiments, each x and y are independently 1. In some embodiments, each x and y are independently 2. In some embodiments, each x and y are independently 3. In some embodiments, each x and y are independently 4.
  • each x and y are selected from those depicted in Table 1, below.
  • the present invention provides a compound of formula I-a, wherein L x is an amide as shown, to provide a compound of formula I-c-1:
  • each of DIM, L, X, R, R x , R y , Ring P, Ring Q, Ring T, , x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a, wherein L x is a thioamide as shown, to provide a compound of formula I-c-2:
  • each of DIM, L, X, R, R x , R y , Ring P, Ring Q, Ring T, , x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a, wherein L x is a 1,2,4-triazole as shown, to provide a compound of formula I-c-3:
  • each of DIM, L, X, R x , R y , Ring P, Ring Q, Ring T, , x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a, wherein L x is a 1,3,4-oxadiazole as shown, to provide a compound of formula I-c-4:
  • each of DIM, L, X, R x , R y , Ring P, Ring Q, Ring T, , x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a, wherein L x is an oxazole as shown, to provide a compound of formula I-c-5:
  • each of DIM, L, X, R x , R y , Ring P, Ring Q, Ring T, , x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a, wherein L x is a thiazole as shown, to provide a compound of formula I-c-6:
  • each of DIM, L, X, R x , R y , Ring P, Ring Q, Ring T, , x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a, wherein L x is an imidazole as shown, to provide a compound of formula I-c-7:
  • each of DIM, L, X, R x , R y , Ring P, Ring Q, Ring T, , x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a, wherein Ring P and Ring Q form a benzoxazole ring as shown, to provide a compound of formula I-d-1:
  • each of DIM, L, L x , X, R x , R y , Ring T, x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a, wherein Ring P and Ring Q form a benzothiazole ring as shown, to provide a compound of formula I-d-2:
  • each of DIM, L, L x , X, R x , R y , Ring T, x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a, wherein Ring P and Ring Q form an indazole ring as shown, to provide a compound of formula I- d-3:
  • each of DIM, L, L x , X, R x , R y , Ring T, x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a, wherein Ring P and Ring Q form a pyrazolopyridine ring as shown, to provide a compound of formula I-d-4:
  • each of DIM, L, L x , X, R x , R y , Ring T, x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a, wherein Ring P and Ring Q form a 5-azaindazole ring as shown, to provide a compound of formula I-d-5:
  • each of DIM, L, L x , X, R x , R y , Ring T, x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a, wherein Ring P and Ring Q form an imidazo[1,2-a]pyridine ring as shown, to provide a compound of formula I-d-6:
  • each of DIM, L, L x , X, R x , R y , Ring T, x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a, wherein Ring P and Ring Q form an indazole ring, and R x is as shown, to provide a compound of formula I-e-1:
  • each of DIM, L, L x , X, R y , Ring T, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a, wherein Ring Q is benzo, a single R x is–OR, and X is cyclohexyl as shown, to provide a compound of formula I-e-2:
  • each of DIM, L, L x , R x , R y , Ring P, Ring T, x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a, wherein Ring P and Ring Q form an indazole ring, a single R x is–OR, and X is cyclohexyl as shown, to provide a compound of formula I-e-3:
  • each of DIM, L, L x , R x , R y , Ring T, x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a, wherein Ring P and Ring Q form an indazole ring and Ring T is cyclohexyl as shown, to provide a compound of formula I-f-1:
  • each of DIM, L, L x , X, R x , R y , x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a, wherein Ring P and Ring Q form a 4,5,6,7-tetrahydro-2H-indazole ring as shown, to provide a compound of formula I-f-2:
  • each of DIM, L, L x , X, R x , R y , Ring T, x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a, wherein Ring P and Ring Q form a isoindolin-1-one ring as shown, to provide a compound of formula I-f-3:
  • each of DIM, L, L x , X, R x , R y , Ring T, x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a, wherein Ring P and Ring Q form a quinoline ring as shown, to provide a compound of formula I- g-1:
  • each of DIM, L, L x , X, R x , R y , Ring T, x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a, wherein Ring P and Ring Q form a 2H-thieno[2,3-c]pyrazole ring as shown, to provide a compound of formula I-g-2:
  • each of DIM, L, L x , X, R x , R y , Ring T, x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a, wherein Ring P is pyridine and Ring Q is phenyl as shown, to provide a compound of formula I- h-1:
  • each of DIM, L, L x , X, R x , R y , Ring T, x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a, wherein Ring P is pyrazole and Ring Q is phenyl as shown, to provide a compound of formula I- h-2:
  • each of DIM, L, L x , X, R x , R y , Ring T, x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I, wherein IRAK is an IRAK-4 binding moiety thereby forming a compound of formula I-i:
  • the present invention provides a compound of formula I, wherein IRAK is an IRAK-4 binding moiety thereby forming a compound of formula I-j:
  • IRAK is .
  • IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is some embodiments, IRAK is n some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRA
  • IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRA
  • IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is
  • IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is . In some embodiments, IRAK is .
  • IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is
  • IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRA
  • IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRA
  • IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRA
  • IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is
  • IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is . In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments,
  • IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is
  • IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRA
  • IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is In some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is in some embodiments, IRAK is
  • IRAK is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoe
  • IRAK is selected from those depicted in Table 1, below.
  • Ligase Binding Moiety (LBM) LBM
  • brackets e..g, , L is attached to a modifiable carbon, oxygen, or nitrogen atom within DIM or LBM including substitution or replacement of a defined group in DIM or LBM.
  • DIM is LBM.
  • the present invention provides a compound of formula I, wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety thereby forming a compound of formula I-aa:
  • L and IRAK are as defined above and described herein, and wherein:
  • X 1 is a bivalent moiety selected from a covalent bond,–CH 2 –,–CHCF 3 –,–SO 2 –,–S(O)–,–P(O)R–
  • X 2 is a carbon atom or silicon atom
  • X 3 is a bivalent moiety selected from–CR 2 –,–NR–,–O–,–S–, or–Si(R 2 )–;
  • R 1 is hydrogen, deuterium, halogen,–CN,–OR,–SR,–S(O)R,–S(O) 2 R,–N(R) 2 ,–P(O)(OR) 2 ,– P(O)(NR 2 )OR,–P(O)(NR 2 ) 2 ,–Si(OH) 2 R,–Si(OH)(R) 2 ,–Si(R)3, or an optionally substituted C1-4 aliphatic;
  • each R 2 is independently hydrogen, deuterium,–R 6 , halogen,–CN,–NO 2 ,–OR, -SR, -N(R) 2 , - Si(R)3, -S(O) 2 R, -S(O) 2 N(R) 2 , -S(O)R, -C(O)R, -C(O)OR,–C(O)N(R) 2 , -C(O)N(R)OR, - C(R) 2 N(R)C(O)R, -C(R) 2 N(R)C(O)N(R) 2 , -OC(O)R, -OC(O)N(R) 2 , -OP(O)R 2 , - OP(O)(OR) 2 , -OP(O)(OR) 2 , -OP(O)(OR) 2 , -OP(O)(OR) 2 , -OP(O)(OR) 2 ,
  • Ring A is a bi- or tricyclic ring selected from , ,
  • Ring B is a fused ring selected from 6-membered aryl, 6-membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 5 to 7-membered saturated or partially unsaturated carbocyclyl, 5 to 7-membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5-membered heteroaryl with 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur;
  • R 3 is selected from hydrogen, halogen,–OR,–N(R) 2 , or–SR;
  • each R 4 is independently hydrogen, –R 6 , halogen, –CN, –NO 2 , –OR, - SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2 , -S(O)R, -C(O)R, -C(O)OR, – C(O)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , or–N(R)S(O) 2 R;
  • R 5 is hydrogen, C1-4 aliphatic, or–CN
  • each R 6 is independently an optionally substituted group selected from C 1-6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • each R is independently hydrogen, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.
  • a compound of formula I-aa above is provided as a compound of formula I-aa ⁇ or formula I-aa ⁇ :
  • each of IRAK, Ring A, L, L 1 , R 1 , R 2 , X 1 , X 2 , X 3 , and m is as defined above.
  • the present invention provides a compound of Formula I, wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety thereby forming a compound of formula I-bb:
  • L and IRAK are as defined above and described in embodiments herein, and wherein:
  • X 1 is a bivalent moiety selected from a covalent bond,–CH 2 –,–CHCF 3 –,–SO 2 –,–S(O)–,–
  • X 2 is a carbon atom or silicon atom
  • X 3 is a bivalent moiety selected from–CR 2 –,–NR–,–O–,–S–, or–Si(R 2 )–;
  • R 1 is hydrogen, deuterium, halogen,–CN,–OR,–SR,–S(O)R,–S(O) 2 R,–N(R) 2 ,–P(O)(OR) 2 ,– P(O)(NR 2 )OR,–P(O)(NR 2 ) 2 ,–Si(OH) 2 R,–Si(OH)(R) 2 , -Si(R) 3 , or an optionally substituted C 1-4 aliphatic;
  • each R 2 is independently hydrogen, deuterium,–R 6 , halogen,–CN,–NO 2 ,–OR, -SR, -N(R) 2 , - Si(R) 3 , -S(O) 2 R, -S(O) 2 N(R) 2, -S(O)R, -C(O)R, -C(O)OR,–C(O)N(R) 2 , -C(O)N(R)OR, - C(R) 2 N(R)C(O)R, -C(R) 2 N(R)C(O)N(R) 2 , -OC(O)R, -OC(O)N(R) 2 , -OP(O)R 2 , - OP(O)(OR) 2 , -OP(O)(OR) 2 , -OP(O)(OR) 2 , -OP(O)(OR) 2 , -OP(O)(OR) 2 ,
  • Ring A is a bi- or tricyclic ring selected from wherein Ring B is other than imidazo
  • Ring B is other than benzo, wherein Ring B is other than benzo,
  • Ring B is other than benzo
  • Ring B is a fused ring selected from 6-membered aryl, 6-membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 5 to 7-membered saturated or partially unsaturated carbocyclyl, 5 to 7-membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5-membered heteroaryl with 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur;
  • R 3 is selected from hydrogen, halogen,–OR,–N(R) 2 , or–SR;
  • each R 4 is independently hydrogen, –R 6 , halogen, –CN, –NO 2 , –OR, - SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2 , -S(O)R, -C(O)R, -C(O)OR, – C(O)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , or–N(R)S(O) 2 R;
  • R 5 is hydrogen, C 1-4 aliphatic, or–CN;
  • each R 6 is independently an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • n 0, 1, 2, 3 or 4;
  • each R is independently hydrogen, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.
  • the compound of formula I-bb above is provided as a compound of formula I-bb ⁇ or formula I-bb ⁇ :
  • each of IRAK, Ring A, L, R 1 , R 2 , X 1 , X 2 , X 3 , and m is as defined above.
  • the present invention provides a compound of Formula I, wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety thereby forming a compound of formula I-cc:
  • L and IRAK are as defined above and described in embodiments herein, and wherein:
  • X 1 is a bivalent moiety selected from a covalent bond,–CH 2 –,–C(O)–,–C(S)–, o
  • R 1 is hydrogen, deuterium, halogen,–CN,–OR,–SR,–S(O)R,–S(O) 2 R,–NR 2 , or an optionally substituted C 1-4 aliphatic;
  • each R 2 is independently hydrogen, –R 6 , halogen, –CN, –NO 2 , –OR, - SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2 , -S(O)R, -C(O)R, -C(O)OR, – C(O)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , or–N(R)S(O) 2 R;
  • Ring A is a bi- or tricyclic ring selected from
  • Ring B is a fused ring selected from 6-membered aryl, 6-membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 5 to 7-membered saturated or partially unsaturated carbocyclyl, 5 to 7-membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5-membered heteroaryl with 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur;
  • R 3 is selected from hydrogen, halogen,–OR,–N(R) 2 , or–SR;
  • each R 4 is independently hydrogen, –R 6 , halogen, –CN, –NO 2 , –OR, - SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2 , -S(O)R, -C(O)R, -C(O)OR, – C(O)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , or–N(R)S(O) 2 R;
  • R 5 is hydrogen, C1-4 aliphatic, or–CN; each R 6 is independently an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • n 0, 1, 2, 3 or 4;
  • each R is independently hydrogen, or an optionally substituted group selected from C 1-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.
  • Ring B a point of attachment of–(R 2 )m is depicted on Ring B, it is intended, and one of ordinary skill in the art would appreciate, that the point of attachment of–(R 2 )m may be on Ring A and may also be at any available carbon or nitrogen atom on Ring A including the ring to which Ring B is fused.
  • R 4 or R 5 is absent and -R 2 takes the place of the R 4 or R 5 group.
  • R 3 is absent and -R 2 takes the place of the R 3 group.
  • the compound of formula I-cc above is provided as a compound of formula I-cc ⁇ or formula I-cc ⁇ :
  • each of IRAK, Ring A, L, R 1 , R 2 , X 1 , and m is as defined above.
  • the present invention provides a compound of formula I, wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety thereby forming a compound of formula I-dd:
  • L and IRAK are as defined above and described in embodiments herein, and wherein:
  • X 1 is a bivalent moiety selected from a covalent bond,–CH 2 –,–CHCF 3 –,–SO 2 –,–S(O)–,–
  • X 2 is a carbon atom or silicon atom
  • X 3 is a bivalent moiety selected from–CR 2 –,–NR–,–O–,–S–, or–Si(R 2 )–;
  • R 1 is hydrogen, deuterium, halogen,–CN,–OR,–SR,–S(O)R,–S(O) 2 R,–NR 2 ,–P(O)(OR) 2 ,– P(O)(NR 2 )OR,–P(O)(NR 2 ) 2 ,–Si(OH) 2 R,–Si(OH)(R) 2 ,–Si(R)3, or an optionally substituted C 1-4 aliphatic;
  • Ring C is a mono- or bicyclic ring selected from , ,
  • each of R 2 and R 3a is independently hydrogen, deuterium,–R 6 , halogen,–CN,–NO 2 ,–OR, - SR, -N(R) 2 , -Si(R)3, -S(O) 2 R, -S(O) 2 N(R) 2 , -S(O)R, -C(O)R, -C(O)OR, – C(O)N(R) 2 , -C(O)N(R)OR, -C(R) 2 N(R)C(O)R, - C(R) 2 N(R)C(O)N(R) 2 , -OC(O)R, -OC(O)N(R) 2 , -OP(O)R 2 , -OP(O)(OR) 2 , -OP(O)(OR) 2 , -OP(O)(OR) 2 , -OP(O)(OR) 2 , -OP(O)
  • Ring D is selected from a 6-membered aryl, 6-membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 5 to 7-membered saturated or partially unsaturated carbocyclyl, 5 to 7-membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5-membered heteroaryl with 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur;
  • each R 4 is independently hydrogen, –R 6 , halogen, –CN, –NO 2 , –OR, - SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2, -S(O)R, -C(O)R, -C(O)OR, – C(O)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , or–N(R)S(O) 2 R;
  • R 5 is hydrogen, C1-4 aliphatic, or–CN
  • each R 6 is independently an optionally substituted group selected from C 1-6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • n 0, 1, 2, 3 or 4;
  • p is 0 or 1, wherein when p is 0, the bond connecting Ring C and Ring D is connected to
  • each R is independently hydrogen, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.
  • a compound of formula I-dd above is provided as a compound of formula I-dd ⁇ or formula I-dd ⁇ :
  • each of IRAK, Ring C, Ring D, L, L 1 , R 1 , R 2 , R 3a , X 1 , X 2 , X 3 , n, m, and p is as defined above.
  • the present invention provides a compound of Formula I, wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety thereby forming a compound of formula I-ee:
  • L and IRAK are as defined above and described in embodiments herein, and wherein:
  • X 1 is a bivalent moiety selected from a covalent bond,–CH 2 –,–C(O)–,–C(S)–, or
  • R 1 is hydrogen, deuterium, halogen,–CN,–OR,–SR,–S(O)R,–S(O) 2 R,–NR 2 , or an optionally substituted C 1-4 aliphatic;
  • Ring C is a mono- or bicyclic ring selected from
  • each of R 2 and R 3a is independently hydrogen, –R 6 , halogen, –CN, –NO 2 , –OR, - SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2 , -S(O)R, -C(O)R, -C(O)OR, – C(O)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , or–N(R)S(O) 2 R;
  • Ring D is selected from 6-membered aryl, 6-membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 5 to 7-membered saturated or partially unsaturated carbocyclyl, 5 to 7-membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5-membered heteroaryl with 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur;
  • each R 4 is independently hydrogen, –R 6 , halogen, –CN, –NO 2 , –OR, - SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2 , -S(O)R, -C(O)R, -C(O)OR, – C(O)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , or–N(R)S(O) 2 R;
  • R 5 is hydrogen, C1-4 aliphatic, or–CN
  • each R 6 is independently an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • n 0, 1, or 2;
  • n 0, 1, 2, 3 or 4;
  • p is 0 or 1, wherein when p is 0, the bond connecting Ring C and Ring D is connected to
  • each R is independently hydrogen, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or: two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.
  • a compound of formula I-ee above is provided as a compound of formula I-ee ⁇ or formula I-ee ⁇ :
  • each of IRAK, Ring C, Ring D, L, R 1 , R 2 , R 3a , X 1 , n, m, and p is as defined above.
  • the present invention provides a compound of formula I, wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety thereby forming a compound of formula I-ff:
  • L and IRAK are as defined above and described in embodiments herein, and wherein: X 1 is a bivalent moiety selected from a covalent bond,–CH 2 –,–CHCF 3 –,–SO 2 –,–S(O)–,–
  • X 2 is a carbon atom or silicon atom
  • X 3 is a bivalent moiety selected from–CR 2 –,–NR–,–O–,–S–, or–Si(R 2 )–;
  • R 1 is hydrogen, deuterium, halogen,–CN,–OR,–SR,–S(O)R,–S(O) 2 R,–NR 2 ,–P(O)(OR) 2 ,– P(O)(NR 2 )OR,–P(O)(NR 2 ) 2 ,–Si(OH) 2 R,–Si(OH)(R) 2 ,–Si(R) 3 , or an optionally substituted C 1-4 aliphatic;
  • Ring C is a mono- or bicyclic ring selected from , ,
  • each or R 2 and R 3a is independently hydrogen, deuterium,–R 6 , halogen,–CN,–NO 2 ,–OR, - SR, -N(R) 2 , -Si(R) 3 , -S(O) 2 R, -S(O) 2 N(R) 2, -S(O)R, -C(O)R, -C(O)OR, – C(O)N(R) 2 , -C(O)N(R)OR, -C(R) 2 N(R)C(O)R, - C(R) 2 N(R)C(O)N(R) 2 , -OC(O)R, -OC(O)N(R) 2 , -OP(O)R 2 , -OP(O)(OR) 2 , -OP(O)(OR) 2 , -OP(O)(OR) 2 , -OP(O)(OR) 2 , -OP(O)
  • Ring D is selected from 6-membered aryl, 6-membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 5 to 7-membered saturated or partially unsaturated carbocyclyl, 5 to 7-membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5-membered heteroaryl with 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur;
  • each R 4 is independently hydrogen, –R 6 , halogen, –CN, –NO 2 , –OR, - SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2, -S(O)R, -C(O)R, -C(O)OR, – C(O)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , or–N(R)S(O) 2 R;
  • R 5 is hydrogen, C 1-4 aliphatic, or–CN;
  • each R 6 is independently an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • n 0, 1, 2, 3 or 4;
  • p is 0 or 1
  • each R is independently hydrogen, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • a compound of formula I-ff above is provided as a compound of formula I-ff ⁇ or formula I-ff ⁇ :
  • each of IRAK, Ring C, Ring D, L, L 1 , R 1 , R 2 , R 3a , X 1 , X 2 , X 3 , m, n, and p is as defined above.
  • the present invention provides a compound of Formula I, wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety thereby forming a compound of formula I-gg:
  • L and IRAK are as defined above and described in embodiments herein, and wherein:
  • X 1 is a bivalent moiety selected from a covalent bond,–CH 2 –,–C(O)–,–C(S)–, o
  • R 1 is hydrogen, deuterium, halogen,–CN,–OR,–SR,–S(O)R,–S(O) 2 R,–NR 2 , or an optionally substituted C1-4 aliphatic;
  • each of R 2 , R 3a , and R 4 is independently hydrogen,–R 6 , halogen,–CN,–NO 2 ,–OR, - SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2, -S(O)R, -C(O)R, -C(O)OR, – C(O)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , or–N(R)S(O) 2 R;
  • Ring D is selected from 6-membered aryl, 6-membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 5 to 7-membered saturated or partially unsaturated carbocyclyl, 5 to 7-membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5-membered heteroaryl with 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur;
  • R 5 is hydrogen, C 1-4 aliphatic, or–CN;
  • each R 6 is independently an optionally substituted group selected from C 1-6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • n 0, 1, or 2;
  • n 0, 1, 2, 3, or 4;
  • p is 0 or 1
  • each R is independently hydrogen, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • two R groups on the same nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur.
  • a compound of formula I-gg above is provided as a compound of formula I-gg ⁇ or formula I-gg ⁇ :
  • each of IRAK, Ring C, Ring D, L, R 1 , R 2 , R 3a , X 1 , m, n, and p is as defined above.
  • the present invention provides a compound of Formula I, wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety thereby forming a compound of formula I-hh:
  • L and IRAK are as defined above and described in embodiments herein, and wherein:
  • X 1 is a bivalent moiety selected from a covalent bond, -CH2-, -CHCF3-, -SO2-, -S(O) -, -
  • X 2 is a carbon atom, nitrogen atom, or silicon atom
  • X 3 is a bivalent moiety selected from a covalent bond, -CR2-, -NR-, 0-, S— , or -S1R2-;
  • R 1 is absent, hydrogen, deuterium, halogen, -CN, -OR, SR, -S(0)R, -S(0) 2 R, -NR 2 , - P(0)(OR) 2 , -P(0)(NR 2 )OR, -P(0)(NR 2 ) 2 , -Si(OH) 2 R, -Si(OH)R 2 , -S1R3, or an optionally substituted C M aliphatic;
  • each R is independently hydrogen, or an optionally substituted group selected from Ci-e aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • each R 2 is independently hydrogen, deuterium,–R 6 , halogen,–CN,–NO 2 ,–OR, -SR, -NR 2 , - SiR 3 , -S(O) 2 R, -S(O) 2 NR 2, -S(O)R, -C(O)R, -C(O)OR,–C(O)NR 2 , -C(O)N(R)OR, - C(R) 2 N(R)C(O)R, -C(R) 2 N(R)C(O)N(R) 2 , -OC(O)R, -OC(O)N(R) 2 , -OP(O)R 2 , - OP(O)(OR) 2 , -OP(O)(OR)NR 2 , -OP(O)(OR)NR 2 , -OP(O)(OR)NR 2 , -OP(O)(OR)NR 2 , -OP(O)(
  • each R 6 is independently an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • each of Ring E, Ring F, and Ring G is independently a fused ring selected from 6-membered aryl, 6-membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 5 to 7-membered saturated or partially unsaturated carbocyclyl, 5 to 7- membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5-membered heteroaryl with 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, wherein Ring E, Ring F, and Ring G is independently and optionally substituted with 1-2 oxo groups;
  • Ring F or Ring G, including the carbon atom to which Ring E or Ring G is fused to Ring F.
  • a compound of formula I-hh above is provided as a compound of formula I-hh ⁇ or formula I-hh ⁇ :
  • each of IRAK, Ring E, Ring F, Ring G, L, L 1 , R 1 , R 2 , X 1 , X 2 , X 3 , and m is as defined above.
  • the present invention provides a compound of Formula I, wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety thereby forming a compound of formula I-hh-1 or I-hh-2:
  • L and IRAK are as defined above and described in embodiments herein, and wherein:
  • each R 2 is independently hydrogen, deuterium,–R 6 , halogen,–CN,–NO 2 ,–OR, -SR, -NR 2 , - SiR 3 , -S(O) 2 R, -S(O) 2 NR 2, -S(O)R, -C(O)R, -C(O)OR,–C(O)NR 2 , -C(O)N(R)OR, - C(R) 2 N(R)C(O)R, -C(R) 2 N(R)C(O)N(R) 2 , -OC(O)R, -OC(O)N(R) 2 , -OP(O)R 2 , - OP(O)(OR) 2 , -OP(O)(OR)NR 2 , -OP(O)(OR)NR 2 , -OP(O)(OR)NR 2 , -OP(O)(OR)NR 2 , -OP(O)(
  • each R 6 is independently an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • each of Ring E, Ring F, and Ring G is independently a fused ring selected from 6-membered aryl, 6-membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 5 to 7-membered saturated or partially unsaturated carbocyclyl, 5 to 7- membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5-membered heteroaryl with 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, wherein Ring E, Ring F, and Ring G is independently and optionally substituted with 1-2 oxo groups;
  • each R is independently hydrogen, or an optionally substituted group selected from C 1-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • R 4 , R 10 , R 11 , R 15 , W 1 , W 2 , and X is as defined in WO 2019/099868, the entirety of each of which is herein incorporated by reference.
  • Ring E, Ring F, or Ring G it is intended, and one of ordinary skill in the art would appreciate, that the point of attachment of may be on any available carbon or nitrogen atom on Ring E, Ring F, or Ring G, including the carbon atom to which Ring E or Ring G is fused to Ring F.
  • the present invention provides a compound of Formula I, wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety thereby forming a compound of formula I-ii:
  • L and IRAK are as defined above and described in embodiments herein, and wherein:
  • X 1 is a bivalent moiety selected from a covalent bond,–CH 2 –,–C(O)–,–C(S)–, o
  • R 1 is hydrogen, deuterium, halogen,–CN,–OR,–SR,–S(O)R,–S(O) 2 R,–N(R) 2 , -Si(R) 3 , or an optionally substituted C 1-4 aliphatic;
  • each R is independently hydrogen, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • each R 2 is independently hydrogen, deuterium,–R 6 , halogen,–CN,–NO 2 ,–OR, -SR, -N(R) 2 , - Si(R) 3 , -S(O) 2 R, -S(O) 2 N(R) 2, -S(O)R, -C(O)R, -C(O)OR,–C(O)N(R) 2 , -C(O)N(R)OR, - C(R) 2 N(R)C(O)R, -C(R) 2 N(R)C(O)N(R) 2 , -OC(O)R, -OC(O)N(R) 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)OR, -N(R)C(O)R,
  • each R 6 is independently an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • each of Ring E, Ring F, and Ring G is independently a fused ring selected from 6-membered aryl containing 0-3 nitrogens, 5 to 7-membered saturated or partially unsaturated carbocyclyl, 5 to 7-membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur, wherein Ring E, Ring F, and Ring G is independently and optionally substituted with 1-2 oxo groups; and
  • n 0, 1, 2, 3, or 4.
  • a compound of formula I-ii above is provided as a compound of formula I-ii ⁇ or formula I-ii ⁇ :
  • each of IRAK, L, Ring E, Ring F, Ring G, L, R 1 , R 2 , X 1 , and m is as defined above.
  • the present invention provides a compound of Formula I, wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety thereby forming a compound of formula I-jj:
  • L and IRAK are as defined above and described in embodiments herein, and wherein:
  • X 1 is a bivalent moiety selected from a covalent bond,–CH 2 –,–CHCF 3 –,–SO 2 –,–S(O)–,–
  • X 2 is a carbon atom, nitrogen atom, or silicon atom
  • X 3 is a bivalent moiety selected from a covalent bond,–CR 2 –,–NR–,–O–,–S–, or–SiR 2 –;
  • R 1 is absent, hydrogen, deuterium, halogen,–CN,–OR,–SR,–S(O)R,–S(O) 2 R,–NR 2 ,– P(O)(OR) 2 ,–P(O)(NR 2 )OR,–P(O)(NR 2 ) 2 ,–Si(OH) 2 R,–Si(OH)R 2 , -SiR 3 , or an optionally substituted C1-4 aliphatic;
  • each R is independently hydrogen, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • each R 2 is independently hydrogen, deuterium,–R 6 , halogen,–CN,–NO 2 ,–OR, -SR, -N(R) 2 , - Si(R)3, -S(O) 2 R, -S(O) 2 N(R) 2 , -S(O)R, -C(O)R, -C(O)OR,–C(O)N(R) 2 , -C(O)N(R)OR, - C(R) 2 N(R)C(O)R, -C(R) 2 N(R)C(O)N(R) 2 , -OC(O)R, -OC(O)N(R) 2 , -OP(O)R 2 , - OP(O)(OR) 2 , -OP(O)(OR) 2 , -OP(O)(OR) 2 , -OP(O)(OR) 2 , -OP(O)(OR) 2 ,
  • each R 6 is independently an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • Ring E is a fused ring selected from 6-membered aryl, 6-membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 5 to 7-membered saturated or partially unsaturated carbocyclyl, 5 to 7-membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5-membered heteroaryl with 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur;
  • Ring H is a fused ring selected from a 7-9 membered saturated or partially unsaturated carbocyclyl or heterocyclyl ring with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, wherein Ring E is optionally further substituted with 1-2 oxo groups;
  • a compound of formula I-jj above is provided as a compound of formula I-jj ⁇ or formula I-jj ⁇ :
  • each of IRAK, Ring E, Ring H, L, L 1 , R 1 , R 2 , X 1 , X 2 , X 3 , and m is as defined above.
  • the present invention provides a compound of Formula I, wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety thereby forming a compound of formula I-kk:
  • L and IRAK are as defined above and described in embodiments herein, and wherein:
  • X 1 is a bivalent moiety selected from a covalent bond,–CH 2 –,–C(O)–,–C(S)–, o
  • R 1 is hydrogen, deuterium, halogen,–CN,–OR,–SR,–S(O)R,–S(O) 2 R,–N(R) 2 , -Si(R) 3 , or an optionally substituted C1-4 aliphatic;
  • each R is independently hydrogen, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • each R 2 is independently hydrogen, deuterium,–R 6 , halogen,–CN,–NO 2 ,–OR, -SR, -N(R) 2 , - Si(R)3, -S(O) 2 R, -S(O) 2 N(R) 2 , -S(O)R, -C(O)R, -C(O)OR,–C(O)N(R) 2 , -C(O)N(R)OR, - C(R) 2 N(R)C(O)R, -C(R) 2 N(R)C(O)N(R) 2 , -OC(O)R, -OC(O)N(R) 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)OR, -N(R)C(O)R,
  • each R 6 is independently an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • Ring E is a fused ring selected from 6-membered aryl, 6-membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 5 to 7-membered saturated or partially unsaturated carbocyclyl, 5 to 7-membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5-membered heteroaryl with 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur;
  • Ring H is a ring selected from a 7-9 membered saturated or partially unsaturated carbocyclyl or heterocyclyl ring with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, wherein Ring E is optionally further substituted with 1-2 oxo groups; and
  • n 0, 1, 2, 3, or 4.
  • a compound of formula I-kk above is provided as a compound of formula I-kk ⁇ or formula I-kk ⁇ :
  • each of IRAK, Ring E, Ring H, L, R 1 , R 2 , X 1 , and m is as defined above.
  • the present invention provides the compound of formula I-kk wherein Ring H is 1,3-dihydro-2H-1,4-diazepin-2-one, thereby forming a compound of formula I- kk-1:
  • each of IRAK, L, Ring E, X 1 , R 1 , R 2 , and m is as defined above.
  • the present invention provides a compound of Formula I, wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety thereby forming a compound of formula I-ll:
  • L and IRAK are as defined above and described in embodiments herein, and wherein:
  • X 1 is a bivalent moiety selected from a covalent bond,–CH 2 –,–CHCF 3 –,–SO 2 –,–S(O)–,–
  • X 2 is a carbon atom, nitrogen atom, or silicon atom
  • X 3 is a bivalent moiety selected from a covalent bond,–CR 2 –,–NR–,–O–,–S–, or–SiR 2 –;
  • R 1 is absent, hydrogen, deuterium, halogen,–CN,–OR,–SR,–S(O)R,–S(O) 2 R,–NR 2 ,– P(O)(OR) 2 ,–P(O)(NR 2 )OR,–P(O)(NR 2 ) 2 ,–Si(OH) 2 R,–Si(OH)R 2 , -SiR3, or an optionally substituted C 1-4 aliphatic;
  • each R is independently hydrogen, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • each R 2 is independently hydrogen, deuterium,–R 6 , halogen,–CN,–NO 2 ,–OR, -SR, -N(R) 2 , - Si(R) 3 , -S(O) 2 R, -S(O) 2 N(R) 2, -S(O)R, -C(O)R, -C(O)OR,–C(O)N(R) 2 , -C(O)N(R)OR, - C(R) 2 N(R)C(O)R, -C(R) 2 N(R)C(O)N(R) 2 , -OC(O)R, -OC(O)N(R) 2 , -OP(O)R 2 , - OP(O)(OR) 2 , -OP(O)(OR) 2 , -OP(O)(OR) 2 , -OP(O)(OR) 2 , -OP(O)(OR) 2 ,
  • each R 6 is independently an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • each of Ring I and J is independently a fused ring selected from 6-membered aryl, 6-membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 5 to 7-membered saturated or partially unsaturated carbocyclyl, 5 to 7-membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5-membered heteroaryl with 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur;
  • Ring K is a fused ring selected from a 7-12 membered saturated or partially unsaturated carbocyclyl or heterocyclyl ring with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, wherein Ring H is optionally further substituted with 1- 2 oxo groups;
  • Ring J or Ring K, including the carbon atom to which Ring I, Ring J, and Ring K are fused.
  • a compound of formula I-ll above is provided as a compound of formula I-ll ⁇ or formula I-ll ⁇ :
  • each of IRAK, Ring I, Ring J, Ring K, L, L 1 , R 1 , R 2 , X 1 , X 2 , X 3 , and m is as defined above.
  • the present invention provides a compound of formula I-mm:
  • L and IRAK are as defined above and described in embodiments herein, and wherein:
  • X 1 is a bivalent moiety selected from a covalent bond,–CH 2 –,–C(O)–,–C(S)–, o
  • R 1 is hydrogen, deuterium, halogen,–CN,–OR,–SR,–S(O)R,–S(O) 2 R,–N(R) 2 , -Si(R)3, or an optionally substituted C1-4 aliphatic;
  • each R is independently hydrogen, or an optionally substituted group selected from C 1-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • each R 2 is independently hydrogen, deuterium,–R 6 , halogen,–CN,–NO 2 ,–OR, -SR, -N(R) 2 , - Si(R)3, -S(O) 2 R, -S(O) 2 N(R) 2 , -S(O)R, -C(O)R, -C(O)OR,–C(O)N(R) 2 , -C(O)N(R)OR, - C(R) 2 N(R)C(O)R, -C(R) 2 N(R)C(O)N(R) 2 , -OC(O)R, -OC(O)N(R) 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)OR, -N(R)C(O)R,
  • each R 6 is independently an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • each of Ring I and J is independently a fused ring selected from 6-membered aryl, 6-membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 5 to 7-membered saturated or partially unsaturated carbocyclyl, 5 to 7-membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5-membered heteroaryl with 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur;
  • Ring K is a fused ring selected from a 7-12 membered saturated or partially unsaturated carbocyclyl or heterocyclyl ring with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, wherein Ring H is optionally further substituted with 1- 2 oxo groups; and
  • m 0, 1, 2, 3, or 4.
  • a point of attachment of is depicted on Ring I, Ring J, and Ring K, it is intended, and one of ordinary skill in the art would appreciate, that the point of attachment may be on any available carbon or nitrogen atom on Ring I, Ring J, or Ring K, including the carbon atom to which Ring I, Ring J, and Ring K are fused.
  • a compound of formula I-mm above is provided as a compound of formula I-mm ⁇ or formula I-mm ⁇ :
  • each of IRAK, Ring I, Ring J, Ring K, L, R 1 , R 2 , X 1 , and m is as defined above.
  • the present invention provides the compound of formula I-mm wherein Ring J is pyrrole, thereby forming a compound of formula I-mm-1:
  • each of IRAK, L, Ring I, Ring K, X 1 , R 1 , R 2 , and m is as defined above.
  • the present invention provides a compound of Formula I-nn:
  • Ring M is selected from
  • each of X 1 , X 6 , and X 7 is independently a bivalent moiety selected from a covalent bond,–CH 2 –,
  • each of X 3 and X 5 is independently a bivalent moiety selected from a covalent bond,–CR 2 –,–NR– ,–O–,–S–, or–SiR 2 –;
  • X 4 is a trivalent moiety selected from
  • each R is independently hydrogen, or an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or: two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from nitrogen, oxygen, and sulfur;
  • each R 3a is independently hydrogen, deuterium,–R 6 , halogen,–CN,–NO 2 ,–OR, -SR, -NR 2 , - SiR 3 , -S(O) 2 R, -S(O) 2 NR 2, -S(O)R, -C(O)R, -C(O)OR,–C(O)NR 2 , -C(O)N(R)OR, - C(R) 2 N(R)C(O)R, -C(R) 2 N(R)C(O)N(R) 2 , -OC(O)R, -OC(O)N(R) 2 , -OP(O)R 2 , - OP(O)(OR) 2 , -OP(O)(OR)NR 2 , -OP(O)(OR)NR 2 , -OP(O)(OR)NR 2 , -OP(O)(OR)NR 2 , -OP(O)
  • each R 6 is independently an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • each R 7 is independently hydrogen, deuterium, halogen, –CN, –OR, –SR, –S(O)R,–S(O) 2 R,–NR 2 ,–P(O)(OR) 2 ,–P(O)(NR 2 )OR,–P(O)(NR 2 ) 2 ,–Si(OH)R 2 ,–Si(OH) 2 R, –SiR3, or an optionally substituted C1-4 aliphatic; or
  • R 7 and X 1 or X 3 are taken together with their intervening atoms to form a 5-7 membered saturated, partially unsaturated, carbocyclic ring or heterocyclic ring having 1-3 heteroatoms, independently selected from boron, nitrogen, oxygen, silicon, or sulfur; two R 7 groups on the same carbon are optionally taken together with their intervening atoms to form a 3-6 membered spiro fused ring or a 4-7 membered heterocyclic ring having 1-2 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur;
  • R 7 groups on adjacent carbon atoms are optionally taken together with their intervening atoms to form a 3-7 membered saturated, partially unsaturated, carbocyclic ring or heterocyclic ring having 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or a 7-13 membered saturated, partially unsaturated, bridged heterocyclic ring, or a spiro heterocyclic ring having 1-3 heteroatoms, independently selected from boron, nitrogen, oxygen, silicon, or sulfur;
  • Ring D is selected from 6-membered aryl, 6-membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, 5 to 7-membered saturated or partially unsaturated carbocyclyl, 5 to 7-membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5-membered heteroaryl with 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur;
  • each of X 1 , X 6 , and X 7 is independently a bivalent moiety selected from a covalent bond,–CH 2 –,–C(R) 2 –,–C(O)–,–C(S)–,–CH(R)–,–
  • each of X 1 , X 6 , and X 7 is independently a covalent bond. In some embodiments, each of X 1 , X 6 , and X 7 is independently–CH 2 –. In some embodiments, each of X 1 , X 6 , and X 7 is independently–CR 2 –. In some embodiments, each of X 1 , X 6 , and X 7 is independently–C(O)–. In some embodiments, each of X 1 , X 6 , and X 7 is independently–C(S)–. In some embodiments, each of X 1 , X 6 , and X 7 is independently–CH(R)–.
  • each of X 1 , X 6 , and X 7 is independently–CH(CF 3 )–. In some embodiments, each of X 1 , X 6 , and X 7 is independently–P(O)(OR)–. In some embodiments, each of X 1 , X 6 , and X 7 is independently– P(O)(R)–. In some embodiments, each of X 1 , X 6 , and X 7 is independently–P(O)NR 2 –. In some embodiments, each of X 1 , X 6 , and X 7 is independently–S(O)–. In some embodiments, each of X 1 , X 6 , and X 7 is independently–S(O) 2 –. In some embodiments, each of X 1 , X 6 , and X 7 is independently–S(O) 2 –. In some embodiments, each of X 1 , X 6 , and X 7 is independently–CH(CF 3 )–. In some
  • each of X 1 , X 6 , and X 7 is independently selected from those depicted in Table 1 below.
  • X 2 is a carbon atom, nitrogen atom, or silicon atom.
  • X 2 is a carbon atom. In some embodiments, X 2 is a nitrogen atom. In some embodiments, X 2 is a silicon atom.
  • X 2 is selected from those depicted in Table 1 below.
  • X 3 is a bivalent moiety selected from–CH 2 –, –CR 2 –,–NR–,–CF2–,–CHF–,–S–,–CH(R)–,–SiR 2 –, or–O–.
  • each of X 3 and X 5 is independently–CH 2 –. In some embodiments, each of X 3 and X 5 is independently–CR 2 –. In some embodiments, each of X 3 and X 5 is independently–NR–. In some embodiments, each of X 3 and X 5 is independently–CF2–. In some embodiments, each of X 3 and X 5 is independently–CHF–. In some embodiments, each of X 3 and X 5 is independently–S–. In some embodiments, each of X 3 and X 5 is independently– CH(R)–. In some embodiments, each of X 3 and X 5 is independently–SiR 2 –. In some embodiments, each of X 3 and X 5 is independently–O–.
  • each of X 3 and X 5 is independently selected from those depicted in Table 1 below.
  • X 4 is a trivalent moiety selected from [00107] In some embodiments, X 4 is In some embodiments, X 4 is In some embodiments, X 4 is In some embodiments, X 4 is . In some embodiments, X 4 is In some embodiments, X 4 is a trivalent moiety selected from [00107] In some embodiments, X 4 is In some embodiments, X 4 is In some embodiments, X 4 is In some embodiments, X 4 is . In some embodiments, X 4 is In some embodiments, X 4 is In some embodiments, X 4 is a trivalent moiety selected from [00107] In some embodiments, X 4 is In some embodiments, X 4 is In some embodiments, X 4 is In some embodiments, X 4 is In some embodiments, X 4 is In some embodiments, X 4 is In some embodiments, X 4 is a trivalent moiety selected from [00107] In some embodiments, X 4 is In some embodiments, X 4 is
  • X 4 is selected from those depicted in Table 1 below.
  • R 1 is hydrogen, deuterium, halogen,–CN,– OR,–SR,–S(O)R,–S(O) 2 R,–NR 2 ,–P(O)(OR) 2 ,–P(O)(NR 2 )OR,–P(O)(NR 2 ) 2 ,–Si(OH) 2 R,– Si(OH)R 2 ,–SiR 3 , an optionally substituted C 1-4 aliphatic, or R 1 and X 1 or X 4 are taken together with their intervening atoms to form a 5-7 membered saturated, partially unsaturated, carbocyclic ring or heterocyclic ring having 1-3 heteroatoms, independently selected from nitrogen, oxygen, or sulfur.
  • R 1 is hydrogen. In some embodiments, R 1 is deuterium. In some embodiments, R 1 is halogen. In some embodiments, R 1 is–CN. In some embodiments, R 1 is–OR. In some embodiments, R 1 is–SR. In some embodiments, R 1 is–S(O)R. In some embodiments, R 1 is–S(O) 2 R. In some embodiments, R 1 is–NR 2 . In some embodiments, R 1 is– P(O)(OR) 2 . In some embodiments, R 1 is–P(O)(NR 2 )OR. In some embodiments, R 1 is about P(O)(NR 2 ) 2 . In some embodiments, R 1 is–Si(OH) 2 R.
  • R 1 is–Si(OH)R 2 . In some embodiments, R 1 is–SiR3. In some embodiments, R 1 is an optionally substituted C1-4 aliphatic. In some embodiments, R 1 and X 1 or X 4 are taken together with their intervening atoms to form a 5-7 membered saturated, partially unsaturated, carbocyclic ring or heterocyclic ring having 1-3 heteroatoms, independently selected from nitrogen, oxygen, or sulfur.
  • R 1 is selected from those depicted in Table 1 below.
  • each R is independently hydrogen, deuterium, or an optionally substituted group selected from C 1-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, and sulfur, or two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from boron, nitrogen, oxygen, silicon, and sulfur.
  • R is hydrogen. In some embodiments, R is deuterium. In some embodiments, R is optionally substituted C1-6 aliphatic. In some embodiments, R is optionally substituted phenyl. In some embodiments, R is optionally substituted 4-7 membered saturated or partially unsaturated heterocyclic having 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, and sulfur. In some embodiments, R is optionally substituted 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, and sulfur.
  • two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from boron, nitrogen, oxygen, silicon, and sulfur.
  • R is selected from those depicted in Table 1 below.
  • each of R 2 and R 3a is independently hydrogen, deuterium, –R 6 , halogen, –CN, –NO 2 , –OR, –Si(OH) 2 R, –Si(OH)R 2 , -SR, -NR 2 , - SiR 3 , -S(O) 2 R, -S(O) 2 NR 2, -S(O)R, -C(O)R, -C(O)OR, –C(O)NR 2 , -C(O)N(R)OR, - C(R) 2 N(R)C(O)R, -C(R) 2 N(R)C(O)NR 2 , -OC(O)R, -OC(O)NR 2 , -OP(O)R 2 , -OP(O)(OR) 2 , -OP(O)(OR) 2 , -OP(O)(OR) 2 , -OP(O)(OR) 2
  • R 2 and R 3a is independently hydrogen. In some embodiments, R 2 and R 3a is independently deuterium. In some embodiments, R 2 and R 3a is independently–R 6 . In some embodiments, R 2 and R 3a is independently halogen. In some embodiments, R 2 and R 3a is independently–CN. In some embodiments, R 2 and R 3a is independently–NO 2 . In some embodiments, R 2 and R 3a is independently–OR. In some embodiments, R 2 and R 3a is independently–Si(OH) 2 R. In some embodiments, R 2 and R 3a is independently–Si(OH)R 2 . In some embodiments, R 2 and R 3a is independently–SR.
  • R 2 and R 3a is independently -NR 2 . In some embodiments, R 2 and R 3a is independently –SiR3. In some embodiments, R 2 and R 3a is independently -S(O) 2 R. In some embodiments, R 2 and R 3a is independently -S(O) 2 NR 2 . In some embodiments, R 2 and R 3a is independently–S(O)R. In some embodiments, R 2 and R 3a is independently–C(O)R. In some embodiments, R 2 and R 3a is independently–C(O)OR. In some embodiments, R 2 and R 3a is independently–C(O)NR 2 . In some embodiments, R 2 and R 3a is independently–C(O)N(R)OR.
  • R 2 and R 3a is independently -C(R) 2 N(R)C(O)R. In some embodiments, R 2 and R 3a is independently - C(R) 2 N(R)C(O)NR 2 . In some embodiments, R 2 and R 3a is independently–OC(O)R. In some embodiments, R 2 and R 3a is independently–OC(O)NR 2 . In some embodiments, R 2 and R 3a is independently -OP(O)R 2 . In some embodiments, R 2 and R 3a is independently -OP(O)(OR) 2 . In some embodiments, R 2 and R 3a is independently -OP(O)(OR)NR 2 .
  • R 2 and R 3a is independently -OP(O)(NR 2 ) 2 -. In some embodiments, R 2 and R 3a is independently– N(R)C(O)OR. In some embodiments, R 2 and R 3a is independently–N(R)C(O)R. In some embodiments, R 2 and R 3a is independently–N(R)C(O)NR 2 . In some embodiments, R 2 and R 3a is independently -NP(O)R 2 . In some embodiments, R 2 and R 3a is independently -N(R)P(O)(OR) 2 . In some embodiments, R 2 and R 3a is independently -N(R)P(O)(OR)NR 2 . In some embodiments, R 2 and R 3a is independently -N(R)P(O)(NR 2 ) 2 . In some embodiments, R 2 and R 3a is independently –N(R)S(O) 2 R.
  • R 2 and R 3a is independently–OH. In some embodiments, R 2 and R 3a is independently–NH 2 . In some embodiments, R 2 and R 3a is independently -CH 2 NH 2 . In some embodiments, R 2 and R 3a is independently -CH 2 NHCOMe. In some embodiments, R 2 and R 3a is independently–CH 2 NHCONHMe. In some embodiments, R 2 and R 3a is independently - NHCOMe. In some embodiments, R 2 and R 3a is independently–NHCONHEt. In some embodiments, R 2 and R 3a is independently -SiMe3. In some embodiments, R 2 and R 3a is independently–SiMe2OH.
  • R 2 and R 3a is independently–SiMe(OH) 2 . In some embodiments R 2 and R 3a is independently In some embodiments, R 2 and R 3a is independently Br. In some embodiments, R 2 and R 3a is independently Cl. In some embodiments, R 2 and R 3a is independently F. In some embodiments, R 2 and R 3a is independently Me. In some embodiments, R 2 and R 3a is independently–NHMe. In some embodiments, R 2 and R 3a is independently–NMe2. In some embodiments, R 2 and R 3a is independently–NHCO 2 Et. In some embodiments, R 2 and R 3a is independently–CN. In some embodiments, R 2 and R 3a is independently -CH 2 Ph.
  • R 2 and R 3a is independently -NHCO 2 tBu. In some embodiments, R 2 and R 3a is independently -CO 2 tBu. In some embodiments, R 2 and R 3a is independently -OMe. In some embodiments, R 2 and R 3a is independently–CF 3 .
  • R 2 or R 3a is selected from those depicted in Table 1 below.
  • R 3 is hydrogen, deuterium, halogen,–CN,– NO 2 ,–OR,–NR 2 ,–SR,–S(O) 2 R,–S(O) 2 NR 2 ,–S(O)R,–C(O)R,–C(O)OR,–C(O)NR 2 ,– C(O)NR(OR),–OC(O)R,–OC(O)NR 2 ,–OP(O)(OR) 2 ,–OP(O)(NR 2 ) 2 ,–OP(O)(OR)NR 2 ,– N(R)C(O)R,–N(R)C(O)OR, -N(R)C(O)NR 2 ,–N(R)S(O) 2 R,–N(R)S(O) 2 NR 2 ,–N(R)P(O)(OR)NR 2 , –N(R)P(O)(OR)NR 2 ,–P(O)(OR)NR 2 ,–P(O
  • R 3 is hydrogen. In some embodiments, R 3 is deuterium. In some embodiments, R 3 is halogen. In some embodiments, R 3 is–CN. In some embodiments, R 3 is–NO 2 . In some embodiments, R 3 is–OR. In some embodiments, R 3 is–NR 2 . In some embodiments, R 3 is–SR. In some embodiments, R 3 is–S(O) 2 R. In some embodiments, R 3 is– S(O) 2 NR 2. In some embodiments, R 3 is–S(O)R. In some embodiments, R 3 is–C(O)R. In some embodiments, R 3 is–C(O)OR. In some embodiments, R 3 is–C(O)NR 2 .
  • R 3 is–C(O)NR(OR). In some embodiments, R 3 is–OC(O)R. In some embodiments, R 3 is– OC(O)NR 2 . In some embodiments, R 3 is–OP(O)(OR) 2 . In some embodiments, R 3 is– OP(O)(NR 2 ) 2 . In some embodiments, R 3 is–OP(O)(OR)NR 2 . In some embodiments, R 3 is about N(R)C(O)R. In some embodiments, R 3 is–N(R)C(O)OR. In some embodiments, R 3 is about N(R)C(O)NR 2 . In some embodiments, R 3 is–N(R)S(O) 2 R.
  • R 3 is– N(R)S(O) 2 NR 2 . In some embodiments, R 3 is–N(R)P(O)(OR) 2 . In some embodiments, R 3 is– N(R)P(O)(OR)NR 2 . In some embodiments, R 3 is–P(O)(OR) 2 . In some embodiments, R 3 is– P(O)(NR 2 )OR. In some embodiments, R 3 is–P(O)(NR 2 ) 2 . In some embodiments, R 3 is–Si(OH) 2 R. In some embodiments, R 3 is aboutSi(OH)(R) 2 . In some embodiments, R 3 is–Si(R)3.
  • R 3 is methyl. In some embodiments, R 3 is–OCH 3 . In some embodiments, R 3 is chloro.
  • R 3 is selected from those depicted in Table 1.
  • each R 4 is independently hydrogen, deuterium, –R 6 , halogen,–CN,–NO 2 ,–OR, -SR, -NR 2 ,–S(O) 2 R,–S(O) 2 NR 2, –S(O)R,–C(O)R,–C(O)OR,– C(O)NR 2 , –C(O)N(R)OR, –OC(O)R, –OC(O)NR 2 , –N(R)C(O)OR, –N(R)C(O)R, – N(R)C(O)NR 2 ,–N(R)S(O) 2 R,–P(O)(OR) 2 ,–P(O)(NR 2 )OR, or–P(O)(NR 2 ) 2 .
  • R 4 is hydrogen. In some embodiments, R 4 is–R 6 . In some embodiments, R 4 is halogen. In some embodiments, R 4 is–CN. In some embodiments, R 4 is– NO 2 . In some embodiments, R 4 is–OR. In some embodiments, R 4 is–SR. In some embodiments, R 4 is–NR 2 . In some embodiments, R 4 is–S(O) 2 R. In some embodiments, R 4 is–S(O) 2 NR 2 . In some embodiments, R 4 is–S(O)R. In some embodiments, R 4 is–C(O)R. In some embodiments, R 4 is–C(O)OR.
  • R 4 is–C(O)NR 2 . In some embodiments, R 4 is– C(O)N(R)OR. In some embodiments, R 4 is–OC(O)R. In some embodiments, R 4 is–OC(O)NR 2 . In some embodiments, R 4 is–N(R)C(O)OR. In some embodiments, R 4 is–N(R)C(O)R. In some embodiments, R 4 is–N(R)C(O)NR 2 . In some embodiments, R 4 is–N(R)S(O) 2 R. In some embodiments, R 4 is–P(O)(OR) 2 . In some embodiments, R 4 is–P(O)(NR 2 )OR. In some embodiments, R 4 is–P(O)(NR 2 ) 2 .
  • R 4 is methyl. In some embodiments, R 4 is ethyl. In some embodiments, R 4 is cyclopropyl.
  • R 4 is selected from those depicted in Table 1.
  • R 5 is hydrogen, deuterium, an optionally substitute C1-4 aliphatic, or–CN.
  • R 5 is hydrogen. In some embodiments, R 5 is deuterium. In some embodiments, R 5 is an optionally substituted C 1-4 aliphatic. In some embodiments, R 5 is– CN.
  • R 5 is selected from those depicted in Table 1.
  • each R 6 is independently an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, and sulfur.
  • R 6 is an optionally substituted C1-6 aliphatic. In some embodiments, R 6 is an optionally substituted phenyl. In some embodiments, R 6 is an optionally substituted 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, and sulfur. In some embodiments, R 6 is an optionally substituted 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, and sulfur.
  • R 6 is selected from those depicted in Table 1.
  • each R 7 is independently hydrogen, deuterium, halogen,– CN,–OR,–SR,–S(O)R,–S(O) 2 R,–N(R) 2 ,–P(O)(R) 2 , -P(O)(OR) 2 , -P(O)(NR 2 )OR, -P(O)(NR 2 ) 2 , -Si(OH)R 2 , -Si(OH) 2 R, -SiR 3 , or an optionally substituted C 1-4 aliphatic, or R 1 and X 1 or X 3 are taken together with their intervening atoms to form a 5-7 membered saturated, partially unsaturated, carbocyclic ring or heterocyclic ring having 1-3 heteroatoms, independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or two R 7 groups on the same carbon are optionally taken together with their intervening atoms to form a 3-6 membered spir
  • R 7 is hydrogen. In some embodiments, R 7 is deuterium. In some embodiments, R 7 is halogen. In some embodiments, R 7 is -CN. In some embodiments, R 7 is -OR. In some embodiments, R 7 is -SR. In some embodiments, R 7 is–S(O)R. In some embodiments, R 7 is–S(O) 2 R. In some embodiments, R 7 is–NR 2 . In some embodiments, R 7 is– Si(R)3. In some embodiments, R 7 is–P(O)(R) 2 . In some embodiments, R 7 is -P(O)(OR) 2 . In some embodiments, R 7 is -P(O)(NR 2 )OR.
  • R 7 is -P(O)(NR 2 ) 2 . In some embodiments, R 7 is -Si(OH)R 2 . In some embodiments, R 7 is -Si(OH) 2 R. In some embodiments, R 7 is an optionally substituted C1-4 aliphatic. In some embodiments, R 7 and X 1 or X 3 are taken together with their intervening atoms to form a 5-7 membered saturated, partially unsaturated, carbocyclic ring or heterocyclic ring having 1-3 heteroatoms, independently selected from boron, nitrogen, oxygen, silicon, or sulfur.
  • two R 7 groups on the same carbon are optionally taken together with their intervening atoms to form a 3-6 membered spiro fused ring or a 4-7 membered heterocyclic ring having 1-2 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur.
  • two R 7 groups on adjacent carbon atoms are optionally taken together with their intervening atoms to form a 3-7 membered saturated, partially unsaturated, carbocyclic ring or heterocyclic ring having 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur.
  • two R 7 groups on adjacent carbon atoms are optionally taken together with their intervening atoms to form a 7-13 membered saturated, partially unsaturated, bridged heterocyclic ring, or a spiro heterocyclic ring having 1-3 heteroatoms, independently selected from boron, nitrogen, oxygen, silicon, or sulfur.
  • R 7 is selected from hydrogen, halogen, -CN, -OR, -NR 2 , or C1- 4 alkyl. In some embodiments, R 7 is selected from hydrogen, halogen, -CN, or C1-4 alkyl. In some embodiments, R 7 is fluoro. In some embodiments, two R 7 groups on the same carbon are optionally taken together with their intervening atoms to form a 3- or 4- membered spiro fused ring.
  • R 7 is selected from those depicted in Table 1 below.
  • Ring A is a bi- or tricyclic ring selected from
  • Ring A is In some embodiments, Ring A is
  • Ring A is In some embodiments, Ring
  • Ring A is In some embodiments, Ring A is In some embodiments,
  • Ring A is In some embodiments, Ring A is In some embodiments, Ring A is In some embodiments, Ring A is In some embodiments, Ring A is In some embodiments, Ring A is In some
  • Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is
  • Ring A is . In some embodiments, Ring A is . In some
  • Ring A is . In some embodiments, Ring A is
  • Ring A is . In some embodiments,
  • Ring A is . In some embodiments, Ring A is
  • Ring A is . In some embodiments, Ring A is
  • Ring A is . In some embodiments, Ring
  • A is .
  • Ring A is selected from those depicted in Table 1 below.
  • Ring B is a fused ring selected from 6- membered aryl, 6-membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 5 to 7-membered saturated or partially unsaturated carbocyclyl, 5 to 7-membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5-membered heteroaryl with 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur;
  • Ring B is a fused 6-membered aryl. In some embodiments, Ring B is a fused 6-membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring B is a fused 5 to 7-membered saturated or partially unsaturated carbocyclyl. In some embodiments, Ring B is fused 5 to 7-membered saturated or partially saturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur. In some embodiments, Ring B is fused 5-membered heteroaryl with 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur.
  • Ring B is . In some embodiments, Ring B is
  • Ring B is . In some embodiments, Ring
  • Ring B is . In some embodiments, Ring B is .
  • each Ring B is . In some embodiments, each Ring B is . In some embodiments, each Ring B is . In some embodiments, each Ring B is . In some embodiments, Ring B is .
  • Ring B is . In some embodiments, Ring B is
  • Ring B is . In some embodiments, Ring B is . In some embodiments, Ring B is . In some embodiments, Ring B is . In some embodiments, Ring B is . [00145] In some embodiments, Ring B is . In some embodiments, Ring B is
  • Ring B is . In some embodiments, Ring B is
  • Ring B is . In some embodiments, Ring B is
  • Ring B is .
  • Ring B is . In some embodiments, Ring B is
  • Ring B is . In some embodiments, Ring B
  • Ring B is .
  • Ring B is selected from those depicted in Table 1 below.
  • Ring C is a mono- or bicyclic ring selected
  • Ring C is In some embodiments, Ring C is
  • Ring C is In some embodiments, Ring
  • Ring C is In some embodiments, Ring C is In some embodiments,
  • Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . [00150] In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is .
  • Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is
  • Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is . In some embodiments, Ring C is In some embodiments, Ring C is In some embodiments, Ring C is In some embodiments,
  • Ring C is
  • Ring C is a mono- or bicyclic ring selected from
  • Ring C is selected from those depicted in Table 1 below.
  • Ring D is a ring selected from 6-membered aryl, 6-membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 5 to 7-membered saturated or partially unsaturated carbocyclyl, 5 to 7-membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5-membered heteroaryl with 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur;
  • Ring D is a 6-membered aryl. In some embodiments, Ring D is a 6-membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, Ring D is a 5 to 7-membered saturated or partially unsaturated carbocyclyl. In some embodiments, Ring D is 5 to 7-membered saturated or partially saturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur. In some embodiments, Ring D is 5-membered heteroaryl with 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur.
  • Ring D is selected from those depicted in Table 1 below.
  • each of Ring E, Ring F, and Ring G is independently a fused ring selected from 6-membered aryl, 6-membered heteroaryl containing 1- 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 5 to 7-membered saturated or partially unsaturated carbocyclyl, 5 to 7-membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5-membered heteroaryl with 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, wherein Ring E, Ring F, and Ring G is independently and optionally substituted with 1-2 oxo groups.
  • each of Ring E, Ring F, and Ring G is independently a fused ring selected from 6-membered aryl. In some embodiments, each of Ring E, Ring F, and Ring G is independently a fused ring selected from 6-membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, each of Ring E, Ring F, and Ring G is independently a fused ring selected from a 5 to 7-membered saturated or partially unsaturated carbocyclyl.
  • each of Ring E, Ring F, and Ring G is independently a fused ring selected from a 5 to 7-membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur. In some embodiments, each of Ring E, Ring F, and Ring G is independently a fused ring selected from a 5-membered heteroaryl with 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur. In some embodiments, Ring E, Ring F, and Ring G is independently and optionally substituted with 1-2 oxo grou ps.
  • Ring F is . In some embodiments, Ring
  • Ring F is In some embodiments, Ring F is In some embodiments, Ring F is In some embodiments, Ring F is In some embodiments, Ring F is In some embodiments, Ring F is In some
  • Ring F is . In some embodiments, Ring F is
  • Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is
  • Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is
  • Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is .
  • Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is .
  • Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is
  • Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is . In some embodiments, Ring F is .
  • each of Ring E and Ring G is independently . In some embodiments, each of Ring E and Ring G is independently . In some embodiments, each of Ring E and Ring G is independently . In some embodiments, each of Ring E and Ring G is independently . In some embodiments, each of Ring E and Ring G is independently .
  • each of Ring E and Ring G is independently is . In some embodiments, each of Ring E and Ring G is independently . In some embodiments, each of Ring E and Ring G is independently . In some embodiments, each of Ring E and Ring G is independently . In some embodiments, each of Ring E and Ring G is independently . In some embodiments, each of Ring E and Ring G is independently . [00162] In some embodiments, each of Ring E and Ring G is independently . In some embodiments, each of Ring E and Ring G is independently . In some embodiments, each of Ring E and Ring G is independently . In some embodiments, each of Ring E and Ring G is independently . In some embodiments, each of Ring E and Ring G is independently . In some embodiments, each of Ring E and Ring G is independently .
  • each of Ring E and Ring G is independently . [00163] In some embodiments, Ring E, Ring F, and Ring G is . In some embodiments, Ring E, Ring F, and Ring G is . In some embodiment, Ring E, Ring F, and Ring G is . In some embodiments, Ring E, Ring F, and Ring G is . In some embodiments, Ring E, Ring F, and Ring G is . In some embodiments, Ring E, Ring F, and Ring G is . In some embodiments, Ring E, Ring F, and Ring G is . In some embodiments, Ring E, Ring F, and Ring G is . In some embodiments, Ring E, Ring F, and Ring G is
  • Ring E, Ring F, and Ring G is . In some embodiments, Ring E, Ring F, and Ring G is . In some embodiments, Ring E, Ring F, and Ring G is . In some embodiments, Ring
  • Ring E, Ring F, and Ring G is .
  • Ring E, Ring F, and Ring G is .
  • Ring E, Ring F, and Ring G is
  • Ring E, Ring F, and Ring G is
  • Ring E, Ring F, and Ring G is
  • Ring E, Ring F, and Ring G is .
  • Ring E, Ring F, and Ring G is . In some embodiments, Ring E, Ring F, and Ring G is . In some embodiments, Ring E, Ring F, and Ring G is . In some embodiments, Ring E, Ring F, and Ring G is
  • Ring E, Ring F, and Ring G is . In some embodiments, Ring E, Ring F, and Ring G is . In some embodiments, Ring E, Ring F, and Ring G is . In some embodiments, Ring E, Ring F, and Ring G is . In some embodiments, Ring E, Ring F, and Ring G is In some embodiments, Ring E, Ring F, and Ring G is
  • Ring E, Ring F, and Ring G is In some embodiments, Ring E, Ring F, and Ring G is In some embodiments, Ring E, Ring F, and Ring G is In some embodiments, Ring E, Ring F, and Ring G is In some embodiments, Ring E, Ring F, and Ring G is In some embodiments, Ring E, Ring F, and Ring G is In some embodiments, Ring E, Ring F, and Ring G is In some embodiments, Ring E, Ring F, and Ring G is In some embodiments, Ring E, Ring F, and Ring G is In some embodiments, Ring E, Ring F, and Ring G is . In some embodiments, Ring E, Ring F, and Ring G is In some embodiments, Ring E, Ring F, and Ring G is . In some embodiments, Ring E, Ring F, and Ring G is In some embodiments, Ring E, Ring F, and Ring G is In some embodiments, Ring E, Ring F, and Ring G is . In some embodiments, Ring E, Ring F, and Ring G is In some embodiments, Ring E, Ring F, and Ring
  • Ring E, Ring F, and Ring G is selected from those depicted in Table 1, below.
  • Ring H is a ring selected from a 7-9 membered saturated or partially unsaturated carbocyclyl or heterocyclyl ring with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, wherein Ring E is optionally further substituted with 1-2 oxo groups.
  • Ring H is a ring selected from a 7-9 membered saturated or partially unsaturated carbocyclyl or heterocyclyl ring with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, wherein Ring H is optionally further substituted with 1-2 oxo groups.
  • Ring H is . In some embodiments, Ring
  • Ring H is In some embodiments, Ring H is n some
  • Ring H is In some embodiments, Ring H is . In some embodiments, Ring H is . In some embodiments, Ring H is . In some embodiments, Ring H is . In some embodiments, Ring H is . In some embodiments, Ring H is . In some embodiments, Ring H is . In some embodiments, Ring H is . In some embodiments, Ring H is . In some embodiments, Ring H is . In some embodiments, Ring H is . In some embodiments, Ring H is . In some embodiments, Ring H is . In some embodiments, Ring H is . In some embodiments, Ring H is . In some embodiments, Ring H is . In some embodiments, Ring H is . In some embodiments, Ring H is . In some embodiments, Ring H is . In some embodiments, Ring H is . In some embodiments, Ring H is . In some embodiments, Ring H is . In some embodiments, Ring H is . In some embodiments, Ring H is . In some embodiments, Ring H is . In
  • Ring H is . In some embodiments, Ring H is
  • Ring H is .
  • Ring H is selected from those depicted in Table 1, below.
  • Ring E and Ring H is .
  • each of Ring I and Ring J is independently a fused ring selected from 6-membered aryl, 6-membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 5 to 7-membered saturated or partially unsaturated carbocyclyl, 5 to 7-membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5- membered heteroaryl with 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur
  • each of Ring I and Ring J is independently a 6-membered aryl. In some embodiments, each of Ring I and Ring J is independently a 6-membered heteroaryl containing 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, each of Ring I and Ring J is independently a 5 to 7-membered saturated or partially unsaturated carbocyclyl. In some embodiments, each of Ring I and Ring J is independently a 5 to 7-membered saturated or partially unsaturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur. In some embodiments, each of Ring I and Ring J is independently a 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur. [00173] In some embodiments, each of Ring I and Ring J is independently
  • each of Ring I and Ring J is independently
  • each of Ring I and Ring J is independently
  • each of Ring I and Ring J is independently
  • each of Ring I and Ring J is independently (R 2 ) m
  • Ring I and Ring J is independently is
  • Ring I and Ring J is independently . In some embodiments,
  • Ring I and Ring J is independently .
  • Ring I and Ring J is selected from those depicted in Table 1, below.
  • Ring K is a fused ring selected from a 7-12 membered saturated or partially unsaturated carbocyclyl or heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, wherein Ring H is optionally further substituted with 1-2 oxo groups.
  • Ring K is a fused ring selected from a 7-12 membered saturated or partially unsaturated carbocyclyl.
  • Ring K is a 7-12 membered saturated or partially unsaturated heterocyclyl ring with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur.
  • Ring K is optionally further substituted with 1-2 oxo groups.
  • Ring K is . In some embodiments, Ring
  • Ring K is . In some embodiments, Ring K is . In some embodiments,
  • Ring K is . In some embodiments, Ring K is
  • Ring K is . In some embodiments,
  • Ring K is . In some embodiments, Ring K is
  • Ring K is . some embodiments, Ring K is . In some embodiments, Ring K is
  • Ring K is .
  • Ring K is . In some embodiments, Ring K is
  • Ring K is .
  • Ring K is selected from those depicted in Table 1 below.
  • Ring I, Ring J, and Ring K is .
  • Ring M is selected from ,
  • Ring M is . In some embodiments, Ring M is
  • Ring M is . In some embodiments, Ring M is
  • Ring M is . In some embodiments, Ring M is
  • Ring M is . In some embodiments, Ring M is
  • Ring M is . In some embodiments, Ring
  • Ring M is selected from those depicted in Table 1 below.
  • L 1 is a covalent bond. In some embodiments, L 1 is a C 1-3 aliphatic. In some embodiments, L 1 is–CH 2 –. In some embodiments, L 1 is–C(D)(H)-. In some embodiments, L 1 is -C(D) 2 –. In some embodiments, L 1 is–CH 2 CH 2 –. In some embodiments, L 1 is–NR–. In some embodiments, L 1 is–CH 2 NR–. In some embodiments, L 1 is or–O–. In some embodiments, L 1 is aboutCH 2 O–. In some embodiments, L 1 is–S–. In some embodiments, L 1 is - OC(O)-.
  • L 1 is -C(O)O-. In some embodiments, L 1 is -C(O)-. In some embodiments, L 1 is -S(O)-. In some embodiments, L 1 is -S(O) 2 -,. In some embodiments, L 1 is - NRS(O) 2 -. In some embodiments, L 1 is -S(O) 2 NR-. In some embodiments, L 1 is -NRC(O)-. In some embodiments, L 1 is -C(O)NR-.
  • Ring L 1 is selected from those depicted in Table 1 below.
  • m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16.
  • m is 0. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4. In some embodiments, m is 5. In some embodiments, m is 6. In some embodiments, m is 7. In some embodiments, m is 8. In some embodiments, m is 9. In some embodiments, m is 10. In some embodiments, m is 11. In some embodiments, m is 12. In some embodiments, m is 13. In some embodiments, m is 14. In some embodiments, m is 15. In some embodiments, m is 16.
  • m is selected from those depicted in Table 1 below.
  • n 0, 1, 2, 3 or 4.
  • n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4.
  • n is selected from those depicted in Table 1 below.
  • p is 0 or 1.
  • p is 0. In some embodiments, p is 1. In some embodiments, p is selected from those depicted in Table 1 below.
  • q is 0, 1, 2, 3 or 4.
  • q is 0. In some embodiments, q is 1. In some embodiments, q is 2. In some embodiments, q is 3. In some embodiments, q is 4.
  • q is selected from those depicted in Table 1 below.
  • LBM is . In some embodiments, LBM is
  • LBM is . In some embodiments,
  • LBM is . In some embodiments, LBM is
  • LBM is . In some embodiments,
  • LBM is .
  • LBM is . In some embodiments, LBM
  • LBM is . In some embodiments, LBM is . In some embodiments, LBM is . In some embodiments, LBM is . In some embodiments, LBM is
  • LBM is .
  • LBM is . In some embodiments, LBM is , . In some embodiments, LBM is . In some embodiments, LBM is . In some embodiments, LBM is . In some embodiments, LBM is . In some embodiments, LBM is . In some embodiments, LBM is . In some embodiments, LBM is . In some embodiments, LBM is . In some embodiments, LBM is . In some embodiments, LBM is . In some embodiments, LBM is . In some embodiments, LBM is . In some embodiments, LBM is . In some embodiments, LBM is . In some embodiments, LBM is
  • LBM is . In some embodiments,
  • LBM is . In some embodiments, LBM is
  • LBM is .
  • LBM is selected from those in Table 1 below.
  • the present invention provides the compound of formula I-a or
  • each of X 1 , X 2 , X 3 , R 1 , R 2 , L 1 , Ring A, and m of the LBM, L, and L x , Ring P, Ring T, R, R x , R y , x, and y of the IRAK moiety is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides the compound of formula I-a or
  • each of X 1 , X 2 , X 3 , R 1 , R 2 , L 1 , Ring A, and m of the LBM, L, and L x , Ring T, R, R x , R y , x, and y of the IRAK moiety is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides the compound of formula I-a or
  • each of X 1 , R 1 , R 2 , Ring A, and m of the LBM, L, and L x , Ring P, Ring T, R, R x , R y , x, and y of the IRAK moiety is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides the compound of formula I-a or
  • each of X 1 , R 1 , R 2 , Ring A, and m of the LBM, L, and L x , Ring T, R, R x , R y , x, and y of the IRAK moiety is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides the compound of formula I-a or
  • each of X 1 , R 1 , R 2 , Ring A, and m of the LBM, and L x , Ring P, Ring T, R, R x , R y , x, and y of the IRAK moiety is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides the compound of formula I-a or
  • each of X 1 , R 1 , R 2 , Ring A, and m of the LBM, and L x , Ring T, R, R x , R y , x, and y of the IRAK moiety is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides the compound of formula I-a or
  • Ring Q is benzo, a single R x is–OR, and X is cyclohexyl as shown, to provide a compound of formula as a compound of formula I-e-10:
  • each of R 2 and m of the LBM, L, and L x , Ring P, Ring T, R, R x , R y , x, and y of the IRAK moiety is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides the compound of formula I-a or
  • each of R 2 and m of the LBM, L, and L x , Ring T, R, R x , R y , x, and y of the IRAK moiety is as defined above and described in embodiments herein, both singly and in combination.
  • LBM is an E3 ligase ligand well known to one of ordinary skill in the art including those described in M. Toure, C. M. Crews, Angew. Chem. Int. Ed.2016, 55, 1966, T. Uehara et al.
  • the present invention provides a compound of Formula I, wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety thereby forming a compound of formula I-oo-1, I-oo-2, I-oo-3, I-oo-4, I-oo-5, I-oo-6, I-oo-7, I-oo-8, I-oo-9, or I-oo-10 respectively:
  • the present invention provides a compound of Formula I, wherein LBM is an E3 ubiquitin ligase (cereblon) binding moiety thereby forming a compound of formula I-pp-1, I-pp-2, I-pp-3, I-pp-4, I-pp-5, or I-pp-6 respectively:
  • L and IRAK are as defined above and described in embodiments herein, and wherein each of the variables A, G, G’, Q 1 , Q 2 , Q 3 , Q 4 , R, R’, W, X, Y, Z, , and n is as defined and described in WO 2016/197114 and US 2018/0147202, the entirety of each of which is herein incorporated by reference.
  • LBM is . In some embodiments, LBM is .
  • LBM is . In some embodiments, LBM is
  • LBM is .
  • LBM is . In some embodiments, LBM is
  • LBM is .
  • LBM is selected from those in Table 1 below.
  • the present invention provides a compound of formula I-a or I ⁇ - a, wherein LBM is thalidomide and L x is an amide as shown, to provide a compound of formula I-i-1: I-i-1
  • each of L, X, R, R x , R y , Ring P, Ring Q, Ring T, , x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a or I ⁇ - a, wherein LBM is thalidomide and L x is a thioamide as shown, to provide a compound of formula I-i-2:
  • each of L, X, R, R x , R y , Ring P, Ring Q, Ring T, , x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a or I ⁇ - a, wherein LBM is thalidomide and L x is a 1,2,4-triazole as shown, to provide a compound of formula I-i-3:
  • the present invention provides a compound of formula I-a or I ⁇ - a, wherein LBM is thalidomide and L x is a 1,3,4-oxadiazole as shown, to provide a compound of formula I-i-4:
  • the present invention provides a compound of formula I-a or I ⁇ - a, wherein LBM is thalidomide and L x is an oxazole as shown, to provide a compound of formula I-i-5:
  • the present invention provides a compound of formula I-a or I ⁇ - a, wherein LBM is thalidomide and L x is a thiazole as shown, to provide a compound of formula I-i-6:
  • the present invention provides a compound of formula I-a or I ⁇ - a, wherein LBM is thalidomide and L x is an imidazole as shown, to provide a compound of formula I-i-7:
  • the present invention provides a compound of formula I-a or I ⁇ - a, wherein LBM is thalidomide and Ring P and Ring Q form a benzoxazole ring as shown, to provide a compound of formula I-j-1:
  • each of L, L x , X, R x , R y , Ring T, x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a or I ⁇ - a, wherein LBM is thalidomide and Ring P and Ring Q form a benzothiazole ring as shown, to provide a compound of formula I-j-2:
  • each of L, L x , X, R x , R y , Ring T, x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a or I ⁇ - a, wherein LBM is thalidomide and Ring P and Ring Q form an indazole ring as shown, to provide a compound of formula I-j-3:
  • each of L, L x , X, R x , R y , Ring T, x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a or I ⁇ - a, wherein LBM is thalidomide and Ring P and Ring Q form a pyrazolopyridine ring as shown, to provide a compound of formula I-j-4:
  • each of L, L x , X, R x , R y , Ring T, x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a or I ⁇ - a, wherein LBM is thalidomide, Ring P and Ring Q form an indazole ring, and R x is as shown, to provide a compound of formula I-k-1: I-k-1
  • the present invention provides a compound of formula I-a or I ⁇ -
  • R x is–OR, and X is cyclohexyl as shown, to provide a compound of formula I-k-2 or I-k- 3:
  • each R x is independently hydrogen, deuterium, R z , halogen, -CN, -NO 2 , -OR, - SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2 , -S(O)R, -CFR 2 , -CF2R, -CF 3 , -CR 2 (OR), - CR 2 (NR 2 ), -C(O)R, -C(O)OR, -C(O)NR 2 , - C(S)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , -N(R)S(O) 2 R, -N + (O-)R 2 , -OP(O)R 2 , -N +
  • R x groups are optionally taken together to form an optionally substituted 5-6 membered partially unsaturated or aryl fused ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
  • each R is independently hydrogen, or an optionally substituted group selected from C 1-6 aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • two R groups on the same carbon or nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the carbon or nitrogen, independently selected from nitrogen, oxygen, and sulfur;
  • each R y is independently hydrogen, deuterium, R z , halogen, -CN, -NO 2 , -OR, - SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2, -S(O)R, -CF 2 R, -CF 3 , -CR 2 (OR), - CR 2 (NR 2 ), -C(O)R, -C(O)OR, -C(O)NR 2 , - C(S)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , -N(R)S(O) 2 R, -OP(O)R 2 , -OP(O)(OR) 2 , -OP(O)(OR) 2 ,
  • each R z is independently an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • Ring P is selected from benzo, a 4-7 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring P is optionally substituted with 1-2 oxo groups;
  • Ring T is selected from phenyl, a 4-7 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-9 membered mono- or bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring T is further optionally substituted with 1-2 oxo groups;
  • -Cy x - is an optionally substituted ring selected from a 3-5 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein -Cy x - is optionally substituted with 1-2 oxo groups;
  • each x is 0, 1, 2, 3 or 4;
  • each y is 0, 1, 2, 3 or 4.
  • the present invention provides a compound of formula I-k-2 or I-k-3 above, wherein L x is amide, Ring P is pyrazolyl, Ring T is pyridyl, R is Me, and R y is - CF 3 .
  • the present invention provides a compound of formula I-a or I ⁇ -
  • each R x is independently hydrogen, deuterium, R z , halogen, -CN, -NO 2 , -OR, - SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2 , -S(O)R, -CFR 2 , -CF2R, -CF 3 , -CR 2 (OR), - CR 2 (NR 2 ), -C(O)R, -C(O)OR, -C(O)NR 2 , - C(S)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , -N(R)S(O) 2 R, -N + (O-)R 2 , -OP(O)R 2 , -N +
  • R x groups are optionally taken together to form an optionally substituted 5-6 membered partially unsaturated or aryl fused ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
  • each R is independently hydrogen, or an optionally substituted group selected from C 1-6 aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • two R groups on the same carbon or nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the carbon or nitrogen, independently selected from nitrogen, oxygen, and sulfur;
  • each R y is independently hydrogen, deuterium, R z , halogen, -CN, -NO 2 , -OR, - SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2 , -S(O)R, -CF2R, -CF 3 , -CR 2 (OR), - CR 2 (NR 2 ), -C(O)R, -C(O)OR, -C(O)NR 2 , - C(S)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , -N(R)S(O) 2 R, -OP(O)R 2 , -OP(O)(OR) 2 , -OP(O)(OR) 2
  • each R z is independently an optionally substituted group selected from C 1-6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • Ring T is selected from phenyl, a 4-7 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-9 membered mono- or bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring T is further optionally substituted with 1-2 oxo groups;
  • -Cy x - is an optionally substituted ring selected from a 3-5 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein -Cy x - is optionally substituted with 1-2 oxo groups;
  • each x is 0, 1, 2, 3 or 4;
  • each y is 0, 1, 2, 3 or 4.
  • the present invention provides a compound of formula I-k-6 or I-k-7 above, wherein L x is amide, Ring T is pyridyl, R is Me, and R y is -CF 3 .
  • the present invention provides a compound of formula I-a or I ⁇ -
  • each R x is independently hydrogen, deuterium, R z , halogen, -CN, -NO 2 , -OR, - SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2 , -S(O)R, -CFR 2 , -CF2R, -CF 3 , -CR 2 (OR), - CR 2 (NR 2 ), -C(O)R, -C(O)OR, -C(O)NR 2 , - C(S)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , -N(R)S(O) 2 R, -N + (O-)R 2 , -OP(O)R 2 , -N +
  • R x groups are optionally taken together to form an optionally substituted 5-6 membered partially unsaturated or aryl fused ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
  • each R is independently hydrogen, or an optionally substituted group selected from C 1-6 aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • two R groups on the same carbon or nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the carbon or nitrogen, independently selected from nitrogen, oxygen, and sulfur;
  • each R y is independently hydrogen, deuterium, R z , halogen, -CN, -NO 2 , -OR, - SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2, -S(O)R, -CF 2 R, -CF 3 , -CR 2 (OR), - CR 2 (NR 2 ), -C(O)R, -C(O)OR, -C(O)NR 2 , - C(S)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , -N(R)S(O) 2 R, -OP(O)R 2 , -OP(O)(OR) 2 , -OP(O)(OR) 2 ,
  • each R z is independently an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • Ring P is selected from benzo, a 4-7 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring P is optionally substituted with 1-2 oxo groups;
  • Ring T is selected from phenyl, a 4-7 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-9 membered mono- or bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring T is further optionally substituted with 1-2 oxo groups;
  • each x is 0, 1, 2, 3 or 4;
  • each y is 0, 1, 2, 3 or 4.
  • the present invention provides a compound of formula I-k-6 or I-k-7 above, wherein Ring P is pyrazolyl, Ring T is pyridyl, R is Me, and R y is -CF 3 .
  • the present invention provides a compound of formula I-a or I ⁇ -
  • LBM is thalidomide Ring P and Ring Q form an indazole ring
  • L x is amide
  • a single R x is–OR
  • X is cyclohexyl as shown, to provide a compound of formula I-k-8 or I-k-9:
  • each R x is independently hydrogen, deuterium, R z , halogen, -CN, -NO 2 , -OR, - SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2, -S(O)R, -CFR 2 , -CF 2 R, -CF 3 , -CR 2 (OR), - CR 2 (NR 2 ), -C(O)R, -C(O)OR, -C(O)NR 2 , - C(S)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , -N(R)S(O) 2 R, -N + (O-)R 2 , -OP(O)R 2 , - OP(O
  • R x groups are optionally taken together to form an optionally substituted 5-6 membered partially unsaturated or aryl fused ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
  • each R is independently hydrogen, or an optionally substituted group selected from C 1-6 aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • two R groups on the same carbon or nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the carbon or nitrogen, independently selected from nitrogen, oxygen, and sulfur;
  • each R y is independently hydrogen, deuterium, R z , halogen, -CN, -NO 2 , -OR, - SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2, -S(O)R, -CF 2 R, -CF 3 , -CR 2 (OR), - CR 2 (NR 2 ), -C(O)R, -C(O)OR, -C(O)NR 2 , - C(S)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , -N(R)S(O) 2 R, -OP(O)R 2 , -OP(O)(OR) 2 , -OP(O)(OR) 2 ,
  • each R z is independently an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • Ring T is selected from phenyl, a 4-7 membered saturated or partially unsaturated carbocyclic or heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or a 5-9 membered mono- or bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, wherein Ring T is further optionally substituted with 1-2 oxo groups;
  • each x is 0, 1, 2, 3 or 4;
  • each y is 0, 1, 2, 3 or 4.
  • the present invention provides a compound of formula I-k-8 or I-k-9 above, wherein Ring T is pyridyl, R is Me, and R y is -CF 3 .
  • the present invention provides a compound of formula I-a or I ⁇ -
  • LBM is thalidomide or , Ring P and Ring Q form an indazole ring, Ring T is pyridyl, L x is amide, a single R x is–OR, and X is cyclohexyl as shown, to provide a compound of formula I-k-10 or I-k-11:
  • each R x is independently hydrogen, deuterium, R z , halogen, -CN, -NO 2 , -OR, - SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2, -S(O)R, -CFR 2 , -CF 2 R, -CF 3 , -CR 2 (OR), - CR 2 (NR 2 ), -C(O)R, -C(O)OR, -C(O)NR 2 , - C(S)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , -N(R)S(O) 2 R, -N + (O-)R 2 , -OP(O)R 2 , - OP(O
  • R x groups are optionally taken together to form an optionally substituted 5-6 membered partially unsaturated or aryl fused ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur;
  • each R is independently hydrogen, or an optionally substituted group selected from C 1-6 aliphatic, phenyl, a 3-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • two R groups on the same carbon or nitrogen are optionally taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the carbon or nitrogen, independently selected from nitrogen, oxygen, and sulfur;
  • each R y is independently hydrogen, deuterium, R z , halogen, -CN, -NO 2 , -OR, - SR, -NR 2 , -S(O) 2 R, -S(O) 2 NR 2, -S(O)R, -CF 2 R, -CF 3 , -CR 2 (OR), - CR 2 (NR 2 ), -C(O)R, -C(O)OR, -C(O)NR 2 , - C(S)NR 2 , -C(O)N(R)OR, -OC(O)R, -OC(O)NR 2 , - N(R)C(O)OR, -N(R)C(O)R, -N(R)C(O)NR 2 , -N(R)S(O) 2 R, -OP(O)R 2 , -OP(O)(OR) 2 , -OP(O)(OR) 2 ,
  • each R z is independently an optionally substituted group selected from C1-6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur; each x is 0, 1, 2, 3 or 4; and
  • each y is 0, 1, 2, 3 or 4.
  • the present invention provides a compound of formula I-k-10 or I-k-11 above, wherein R is Me and R y is -CF 3 . [00243] In some embodiments, the present invention provides a compound of formula I-a or I ⁇ -
  • each of variables , Y, R1, R3, R3’, R 4 , R 5 , t, m, n, Ring P, Ring T, L, L x , R x , R y , x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a or I ⁇ -
  • each of variables X 1 , X 2 , X 3 , R 1 , R 2 , Ring A, m, Ring P, Ring T, L, L x , R x , R y , x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a or I ⁇ - a, wherein LBM is , Ring P and Ring Q form an indazole ring, a single R x is–OR, and X is cyclohexyl as shown, to provide a compound of formula I-k-14:
  • each of variables , Y, R1, R3, R3’, R4, R5, t, m, n, Ring T, L, L x , R x , R y , x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a or I ⁇ -
  • each of variables X 1 , X 2 , X 3 , R 1 , R 2 , Ring A, m, Ring T, L, L x , R x , R y , x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a or I ⁇ - a, wherein LBM is thalidomide, Ring P and Ring Q form an indazole ring, and Ring T is cyclohexyl as shown, to provide a compound of formula I-l-1: I-l-1
  • each of L, L x , X, R x , R y , x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a or I ⁇ - a, wherein LBM is thalidomide, Ring P and Ring Q form a 4,5,6,7-tetrahydro-2H-indazole ring as shown, to provide a compound of formula I-l-2:
  • each of L, L x , X, R x , R y , Ring T, x, and y is as defined above and described in embodiments herein, both singly and in combination.
  • the present invention provides a compound of formula I-a or I ⁇ - a, wherein LBM is thalidomide, Ring P and Ring Q form an isoindolin-1-one ring as shown, to provide a compound of formula I-l-3:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PCT/US2020/040125 2019-06-28 2020-06-29 Irak degraders and uses thereof Ceased WO2020264499A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
AU2020302118A AU2020302118A1 (en) 2019-06-28 2020-06-29 IRAK degraders and uses thereof
MX2021015995A MX2021015995A (es) 2019-06-28 2020-06-29 Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos.
BR112021026517A BR112021026517A2 (pt) 2019-06-28 2020-06-29 Degradadores de irak e usos dos mesmos
KR1020227003218A KR20220032063A (ko) 2019-06-28 2020-06-29 Irak 분해제 및 이의 용도
CN202080059563.1A CN114502158A (zh) 2019-06-28 2020-06-29 Irak降解剂及其用途
CA3144805A CA3144805A1 (en) 2019-06-28 2020-06-29 Irak degraders and uses thereof
US17/597,165 US12545659B2 (en) 2019-06-28 2020-06-29 IRAK degraders and uses thereof
EP20833679.2A EP3989966A4 (en) 2019-06-28 2020-06-29 Irak degraders and uses thereof
JP2021577410A JP7687970B2 (ja) 2019-06-28 2020-06-29 Ｉｒａｋ分解剤およびその使用
PH1/2022/500002A PH12022500002A1 (en) 2019-06-28 2020-06-29 Irak degraders and uses thereof
MX2024013970A MX2024013970A (es) 2019-06-28 2021-12-17 Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos
IL289267A IL289267A (en) 2019-06-28 2021-12-22 Iraq joints and their uses
CONC2021/0017893A CO2021017893A2 (es) 2019-06-28 2021-12-27 Degradadores de irak y usos de los mismos
US18/315,267 US20240059674A1 (en) 2019-06-28 2023-05-10 Irak degraders and uses thereof
JP2025085728A JP2025113407A (ja) 2019-06-28 2025-05-22 Ｉｒａｋ分解剤およびその使用
US19/356,388 US20260042749A1 (en) 2019-06-28 2025-10-13 Irak degraders and uses thereof

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US201962868609P 2019-06-28 2019-06-28
US62/868,609 2019-06-28
US201962875407P 2019-07-17 2019-07-17
US62/875,407 2019-07-17
US201962908153P 2019-09-30 2019-09-30
US62/908,153 2019-09-30
US201962944834P 2019-12-06 2019-12-06
US62/944,834 2019-12-06
US201962948968P 2019-12-17 2019-12-17
US62/948,968 2019-12-17
US202062958980P 2020-01-09 2020-01-09
US62/958,980 2020-01-09
US202062964955P 2020-01-23 2020-01-23
US62/964,955 2020-01-23
US202063040891P 2020-06-18 2020-06-18
US63/040,891 2020-06-18

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US17/597,165 A-371-Of-International US12545659B2 (en) 2019-06-28 2020-06-29 IRAK degraders and uses thereof
US18/315,267 Continuation US20240059674A1 (en) 2019-06-28 2023-05-10 Irak degraders and uses thereof
US19/356,388 Division US20260042749A1 (en) 2019-06-28 2025-10-13 Irak degraders and uses thereof

Publications (1)

Publication Number Publication Date
WO2020264499A1 true WO2020264499A1 (en) 2020-12-30

Family

ID=74060700

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/040125 Ceased WO2020264499A1 (en) 2019-06-28 2020-06-29 Irak degraders and uses thereof

Country Status (13)

Country Link
US (2) US12545659B2 (enExample)
EP (1) EP3989966A4 (enExample)
JP (2) JP7687970B2 (enExample)
KR (1) KR20220032063A (enExample)
CN (1) CN114502158A (enExample)
AU (1) AU2020302118A1 (enExample)
BR (1) BR112021026517A2 (enExample)
CA (1) CA3144805A1 (enExample)
CO (1) CO2021017893A2 (enExample)
IL (1) IL289267A (enExample)
MX (2) MX2021015995A (enExample)
PH (1) PH12022500002A1 (enExample)
WO (1) WO2020264499A1 (enExample)

Cited By (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112724079A (zh) * 2021-02-04 2021-04-30 康化（上海）新药研发有限公司 一种6-甲氧基吡啶甲酸甲酯的合成方法
US11318205B1 (en) 2017-12-26 2022-05-03 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2022088551A1 (zh) * 2020-10-26 2022-05-05 上海领泰生物医药科技有限公司 吲唑类衍生物及其制备方法和应用
US11352350B2 (en) 2018-11-30 2022-06-07 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2022161414A1 (zh) * 2021-01-26 2022-08-04 成都茵创园医药科技有限公司 芳香化合物、含其的药物组合物及其应用
WO2022184975A1 (en) * 2021-03-01 2022-09-09 Orion Corporation Process for the preparation of a cyp11a1 inhibitor and intermediates thereof
US20220331330A1 (en) * 2021-04-08 2022-10-20 Curis, Inc. Combination therapies for the treatment of cancer
WO2022257152A1 (en) * 2021-06-11 2022-12-15 Dsm Ip Assets B.V. Process for producing biotin intermediate
WO2022266258A1 (en) * 2021-06-15 2022-12-22 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of irak-4
WO2023283372A1 (en) * 2021-07-07 2023-01-12 Biogen Ma Inc. Compounds for targeting degradation of irak4 proteins
WO2023021081A1 (en) * 2021-08-20 2023-02-23 Henkel Ag & Co. Kgaa Vinyl ethers
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2023025159A1 (zh) * 2021-08-23 2023-03-02 上海领泰生物医药科技有限公司 Irak4降解剂及其制备方法和应用
WO2023045978A1 (zh) * 2021-09-26 2023-03-30 南京明德新药研发有限公司 2,6-哌啶二酮类化合物与其应用
US11685750B2 (en) 2020-06-03 2023-06-27 Kymera Therapeutics, Inc. Crystalline forms of IRAK degraders
WO2023116866A1 (zh) * 2021-12-23 2023-06-29 杭州多域生物技术有限公司 一种五元并六元化合物、制备方法、药物组合物和应用
WO2023116920A1 (zh) * 2021-12-23 2023-06-29 杭州多域生物技术有限公司 一种五元并六元化合物、制备方法、药物组合物和应用
WO2023131167A1 (zh) 2022-01-04 2023-07-13 海思科医药集团股份有限公司 一种抑制并降解irak4的化合物及其药物组合物和药学上的应用
US11707457B2 (en) 2019-12-17 2023-07-25 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2023143249A1 (zh) * 2022-01-28 2023-08-03 上海齐鲁制药研究中心有限公司 靶向malt1的蛋白降解化合物
US11746120B2 (en) 2019-04-05 2023-09-05 Kymera Therapeutics, Inc. Stat degraders and uses thereof
WO2023178323A1 (en) * 2022-03-18 2023-09-21 Henry Ford Health System Therapeutic inhibition of cd38 to treat hidradenitis suppurativa
US11857535B2 (en) 2020-07-30 2024-01-02 Kymera Therapeutics, Inc. Methods of treating mutant lymphomas
WO2024020522A1 (en) * 2022-07-22 2024-01-25 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of irak-4
JP2024517340A (ja) * 2021-05-14 2024-04-19 アプリノイア セラピューティクス リミテッド アルファ－シヌクレイン凝集物を分解する化合物及びその使用
WO2024126617A1 (en) 2022-12-14 2024-06-20 Crossfire Oncology Holding B.V. Bifunctional compounds for degrading kinases via ubiquitin proteosome pathway
JP2024527570A (ja) * 2021-07-07 2024-07-25 バイオジェン・エムエイ・インコーポレイテッド Ｉｒａｋ４タンパク質の分解をターゲティングするための化合物
US12091411B2 (en) 2022-01-31 2024-09-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US12097261B2 (en) 2021-05-07 2024-09-24 Kymera Therapeutics, Inc. CDK2 degraders and uses thereof
WO2024199147A1 (zh) * 2023-03-24 2024-10-03 漳州片仔癀药业股份有限公司 2,6-哌啶二酮类化合物的晶型、制备方法及其应用
WO2024199135A1 (zh) * 2023-03-24 2024-10-03 漳州片仔癀药业股份有限公司 2,6-哌啶二酮类化合物盐型和晶型的制备方法及其应用
WO2024209044A1 (en) 2023-04-07 2024-10-10 Astrazeneca Ab Irak4 protacs
US12150995B2 (en) 2020-12-30 2024-11-26 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2024245331A1 (zh) 2023-05-30 2024-12-05 上海汇伦医药股份有限公司 三并环类化合物、其制备方法和应用
US12171768B2 (en) 2021-02-15 2024-12-24 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof
WO2025003987A1 (ko) * 2023-06-29 2025-01-02 동화약품주식회사 신규한 카르복사마이드 유도체 화합물 및 이를 포함하는 약학적 조성물
US12187744B2 (en) 2021-10-29 2025-01-07 Kymera Therapeutics, Inc. IRAK4 degraders and synthesis thereof
WO2025011655A1 (zh) 2023-07-13 2025-01-16 成都茵创园医药科技有限公司 芳香化合物、含其的药物组合物及其应用
WO2025036285A1 (zh) 2023-08-11 2025-02-20 深圳众格生物科技有限公司 一种降解irak4的蛋白降解靶向嵌合体化合物及其应用
WO2025010326A3 (en) * 2023-07-03 2025-03-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Dimeric immuno-modulatory compounds against cereblon-based mechanisms
WO2025061203A1 (zh) * 2023-09-21 2025-03-27 成都茵创园医药科技有限公司 Irak降解剂及其用途
US20250122192A1 (en) * 2021-12-03 2025-04-17 Rgenta Therapeutics, Inc. 5-pyrimidinecarboxamide derivatives and methods of using the same
WO2025125575A1 (en) * 2023-12-14 2025-06-19 Astrazeneca Ab Irak4 protacs
WO2025126115A1 (en) 2023-12-13 2025-06-19 Beigene Switzerland Gmbh Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligands and methods of use
EP4333836A4 (en) * 2021-05-07 2025-07-23 Kymera Therapeutics Inc DEUTERATED IRAQ DEGRADING AGENTS AND THEIR USES
US12410193B2 (en) 2014-01-13 2025-09-09 Aurigene Oncology Limited Bicyclic heterocyclyl derivatives as IRAK4 inhibitors
EP4620470A3 (en) * 2023-06-23 2025-10-08 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2025221154A1 (en) * 2024-04-17 2025-10-23 Captor Therapeutics S.A. Klhdc2 (kelch domain-containing protein 2) ligase ligands
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US12497402B2 (en) 2021-02-15 2025-12-16 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof
US12516068B2 (en) 2018-01-12 2026-01-06 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US12545659B2 (en) 2019-06-28 2026-02-10 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US12551564B2 (en) 2019-12-10 2026-02-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US12558427B2 (en) 2019-07-17 2026-02-24 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2026061418A1 (en) * 2024-09-18 2026-03-26 Beone Pharmaceutical (Suzhou) Co., Ltd. Dual irak1/irak4 degraders, compositions thereof, and methods of treatment therewith

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023282477A1 (en) * 2022-06-09 2024-12-19 Beone Medicines I Gmbh Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligand and methods of use
CN119630654A (zh) * 2022-06-10 2025-03-14 珠海宇繁生物科技有限责任公司 蛋白质降解剂及其用途
WO2023241644A1 (zh) * 2022-06-15 2023-12-21 杭州多域生物技术有限公司 一种五元并六元化合物、制备方法、药物组合物和应用
CN116925085B (zh) * 2022-07-23 2026-03-31 成都茵创园医药科技有限公司 Irak降解剂及其用途
CN117777126A (zh) * 2022-09-29 2024-03-29 武汉人福创新药物研发中心有限公司 作为irak4降解剂的咪唑并吡啶类化合物及其用途
CN115974703A (zh) * 2022-12-21 2023-04-18 上海泰坦科技股份有限公司 一种羟甲基取代的n,n-二甲基脂环胺的制备方法
CN120641423A (zh) * 2023-03-03 2025-09-12 上海齐鲁制药研究中心有限公司 Irak4降解剂及其应用
CN116768928A (zh) * 2023-06-15 2023-09-19 上海毕臣生化科技有限公司 一种3-叔丁基-5-硼酸酯基吡啶的合成方法
WO2025031482A1 (zh) * 2023-08-09 2025-02-13 武汉人福创新药物研发中心有限公司 作为irak4降解剂的氟代咪唑并吡啶类化合物及其用途
CN118955497B (zh) * 2023-08-21 2025-10-31 泰诺瑞(天津)生物科技有限责任公司 一种咪唑并[1,2-a]吡啶类IRAK4降解剂及其应用
WO2025077891A1 (zh) * 2023-10-13 2025-04-17 江苏先声药业有限公司 靶向irak4的降解剂化合物及其应用
TW202540082A (zh) * 2023-12-13 2025-10-16 大陸商杭州多域生物技術有限公司 一種五員并六員化合物的晶型、其製備方法及應用
WO2025149070A1 (zh) * 2024-01-10 2025-07-17 甘李药业股份有限公司 一种新型靶向白细胞介素1受体关联激酶4(irak4)的蛋白降解嵌合体化合物的合成及其应用

Citations (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5721246A (en) 1993-09-10 1998-02-24 Eisai Co., Ltd. Heterobicyclic sulfonamide and sulfonic ester derivatives
WO2002020740A2 (en) 2000-09-08 2002-03-14 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
US7622496B2 (en) 2005-12-23 2009-11-24 Zealand Pharma A/S Modified lysine-mimetic compounds
WO2012003281A2 (en) 2010-06-30 2012-01-05 Brandeis University Small-molecule-targeted protein degradation
WO2012078559A2 (en) 2010-12-07 2012-06-14 Yale University Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
WO2013106646A2 (en) 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
WO2013106643A2 (en) 2012-01-12 2013-07-18 Yale University Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
WO2014044622A1 (en) 2012-09-19 2014-03-27 F. Hoffmann-La Roche Ag 2-oxo-2,3,4,5-tetrahydro-1 h-benzo[b]diazepines and their use in the treatment of cancer
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014108452A1 (en) 2013-01-11 2014-07-17 Glaxosmithkline Intellectual Property Development Limited Proteolysis targeting chimeras (protacs) directed to the modulation of the estrogen receptor
WO2015071393A1 (en) 2013-11-18 2015-05-21 F. Hoffmann-La Roche Ag Tetrahydro-benzodiazepinones
US20150291562A1 (en) 2014-04-14 2015-10-15 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
US20160022642A1 (en) 2014-07-25 2016-01-28 Yale University Compounds Useful for Promoting Protein Degradation and Methods Using Same
WO2016105518A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US20160214972A1 (en) 2015-01-20 2016-07-28 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
US20160272639A1 (en) 2015-03-18 2016-09-22 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
WO2016169989A1 (en) 2015-04-22 2016-10-27 Glaxosmithkline Intellectual Property Development Limited Iap e3 ligase directed proteolysis targeting chimeric molecules
WO2016197032A1 (en) 2015-06-04 2016-12-08 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2016197114A1 (en) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US20170008904A1 (en) 2015-07-10 2017-01-12 Arvinas, Inc. Mdm2-based modulators of proteolysis and associated methods of use
WO2017011590A1 (en) 2015-07-13 2017-01-19 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
US20170121321A1 (en) 2015-11-02 2017-05-04 Yale University Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same
WO2017108744A1 (de) 2015-12-22 2017-06-29 Bayer Pharma Aktiengesellschaft Neue substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2017117473A1 (en) 2015-12-30 2017-07-06 Dana-Farber Cancer Institute, Inc. Bifunctional molescules for her3 degradation and methods of use
WO2017117474A1 (en) 2015-12-30 2017-07-06 Dana-Farber Cancer Institute, Inc. Bifunctional compounds for her3 degradation and methods of use
WO2017148902A1 (de) 2016-03-03 2017-09-08 Bayer Pharma Aktiengesellschaft Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2017161119A1 (en) 2016-03-16 2017-09-21 H. Lee Moffitt Cancer Center & Research Institute, Inc. Small molecules against cereblon to enhance effector t cell function
US20170281784A1 (en) 2016-04-05 2017-10-05 Arvinas, Inc. Protein-protein interaction inducing technology
WO2017176957A1 (en) 2016-04-06 2017-10-12 The Regents Of The University Of Michigan Mdm2 protein degraders
WO2017176958A1 (en) 2016-04-06 2017-10-12 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2018134684A1 (zh) 2017-01-18 2018-07-26 阿尔卡特朗讯 无线接入网中用于网络切片的资源分配方法和编排器
WO2018237026A1 (en) 2017-06-20 2018-12-27 C4 Therapeutics, Inc. N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS
WO2019043214A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag glutarimide
WO2019084026A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
WO2019099926A1 (en) * 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
WO2019099868A2 (en) 2017-11-16 2019-05-23 C4 Therapeutics, Inc. Degraders and degrons for targeted protein degradation
WO2019165229A1 (en) 2018-02-23 2019-08-29 Dana-Farber Cancer Institute, Inc. Small molecules for inducing selective protein degradation and uses thereof
WO2019236483A1 (en) 2018-06-04 2019-12-12 C4 Therapeutics, Inc. Spirocyclic compounds
WO2020018788A1 (en) 2018-07-20 2020-01-23 Dana-Farber Cancer Institute, Inc. Degraders that target proteins via keap1

Family Cites Families (258)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4045485A (en) 1968-07-02 1977-08-30 Syntex Corporation Naphthyl acetaldehyde derivatives; methods of use thereof; and processes for the preparation thereof
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5360811A (en) 1990-03-13 1994-11-01 Hoechst-Roussel Pharmaceuticals Incorporated 1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents
AU4596096A (en) 1994-09-06 1996-03-27 Banyu Pharmaceutical Co., Ltd. Novel carbapenem derivative
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
CA2269561C (en) 1998-04-22 2007-06-05 Dainippon Ink And Chemicals, Inc. Naphthalene derivative and liquid crystal composition comprising the same
US6306663B1 (en) 1999-02-12 2001-10-23 Proteinex, Inc. Controlling protein levels in eucaryotic organisms
IL131264A0 (en) 1999-08-05 2001-01-28 Yeda Res & Dev Photochromic naphthopyran compounds
DE60037345T2 (de) 1999-12-10 2008-11-13 Pfizer Products Inc., Groton Pyrrolo(2,3-d)pyrimidin-Verbindungen
DE10002509A1 (de) 2000-01-21 2001-07-26 Gruenenthal Gmbh Substituierte Glutarimide
EP1259514B9 (en) 2000-02-28 2005-11-09 Sugen, Inc. 3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US7208157B2 (en) 2000-09-08 2007-04-24 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
DE60217322T2 (de) 2001-04-27 2007-10-04 Zenyaku Kogyo K.K. Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
PT1536827E (pt) 2002-08-14 2009-03-20 Silence Therapeutics Ag Utilização de proteína cinase n beta
AU2004228668B2 (en) 2003-04-03 2011-10-27 Park Funding, Llc PI-3 kinase inhibitor prodrugs
ES2382377T3 (es) 2003-05-30 2012-06-07 Gemin X Pharmaceuticals Canada Inc. Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
EP1692153A4 (en) 2003-07-03 2007-03-21 Univ Pennsylvania INHIBITION OF EXPRESSION OF SYK-KINASE
JP4398263B2 (ja) 2004-01-13 2010-01-13 富士通株式会社 経路設計方法
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
AU2006206458B2 (en) 2005-01-19 2012-10-25 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
PT2343320T (pt) 2005-03-25 2018-01-23 Gitr Inc Anticorpos anti-gitr e as suas utilizações
PL1888550T3 (pl) 2005-05-12 2014-12-31 Abbvie Bahamas Ltd Promotory apoptozy
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
US7989622B2 (en) 2005-10-07 2011-08-02 Exelixis, Inc. Phosphatidylinositol 3-kinase inhibitors and methods of their use
JP5191391B2 (ja) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007129161A2 (en) 2006-04-26 2007-11-15 F. Hoffmann-La Roche Ag Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor
DK2526933T3 (en) 2006-09-22 2015-05-18 Pharmacyclics Inc Inhibitors of Bruton's tyrosine kinase
US20100279316A1 (en) 2007-01-19 2010-11-04 Leonid Gorelik Antibodies to Phosphorylated IRAK4
KR101566840B1 (ko) 2007-03-12 2015-11-06 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 페닐 아미노 피리미딘 화합물 및 이의 용도
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
GB0706793D0 (en) 2007-04-05 2007-05-16 Evotec Ag Compounds
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
US8591886B2 (en) 2007-07-12 2013-11-26 Gitr, Inc. Combination therapies employing GITR binding molecules
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
EP2219671A4 (en) 2007-11-09 2011-02-09 Salk Inst For Biological Studi USE OF TAM RECEPTOR INHIBITORS AS IMMU ENHANCERS AND TAM ACTIVATORS AS IMMUNOSUPPRESSORS
US10047066B2 (en) 2007-11-30 2018-08-14 Newlink Genetics Corporation IDO inhibitors
US20090171093A1 (en) 2007-12-28 2009-07-02 Yoshio Takeuchi 3'-Fluoro-5'-hydroxythalidomide and derivatives thereof
HUE029767T2 (en) 2008-03-11 2017-04-28 Incyte Holdings Corp JAK inhibitor azetidine and cyclobutane derivatives
CA2722159C (en) 2008-04-24 2016-04-05 Newlink Genetics Corporation Substituted phenylimidazole compounds and their use as ido inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
US8921037B2 (en) 2008-12-16 2014-12-30 Bo Han PF4-depleted platelet rich plasma preparations and methods for hard and soft tissue repair
KR101790802B1 (ko) 2009-09-03 2017-10-27 머크 샤프 앤드 돔 코포레이션 항-ｇｉｔｒ 항체
JP2012254939A (ja) 2009-10-07 2012-12-27 Astellas Pharma Inc オキサゾール化合物
EP2493862B1 (en) 2009-10-28 2016-10-05 Newlink Genetics Corporation Imidazole derivatives as ido inhibitors
ES2722300T3 (es) 2009-12-10 2019-08-09 Hoffmann La Roche Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
PL3202460T3 (pl) 2010-02-11 2019-12-31 Celgene Corporation Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania
EP2542256B1 (en) 2010-03-04 2019-05-22 MacroGenics, Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
US9169323B2 (en) 2010-03-05 2015-10-27 Hoffmann-La Roche Inc. Antibodies against human CSF-1R
JP5989547B2 (ja) 2010-03-05 2016-09-07 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ヒトｃｓｆ−１ｒに対する抗体及びその使用
US8114621B2 (en) 2010-03-12 2012-02-14 Saladax Biomedical Inc. Lenalidomide and thalidomide immunoassays
HRP20190047T1 (hr) 2010-05-04 2019-02-22 Five Prime Therapeutics, Inc. Protutijela koja se vežu na csf1r
EP2575884B1 (en) 2010-06-03 2018-07-18 AbbVie Biotechnology Ltd Uses and compositions for treatment of hidradenitis suppurativa (hs)
CN110003219A (zh) 2010-07-13 2019-07-12 弗·哈夫曼-拉罗切有限公司 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物
MX337040B (es) 2010-09-09 2016-02-09 Pfizer Moleculas de union a 4-1bb.
RU2632900C2 (ru) 2010-11-19 2017-10-11 Лиганд Фармасьютикалс Инкорпорейтед Гетероциклические амины и их применение
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
BR112013015460B1 (pt) 2010-12-20 2022-01-25 Merck Serono S.A. Derivados de indazolil triazol, kit, e composição farmacêutica
WO2012097013A1 (en) 2011-01-10 2012-07-19 Nimbus Iris, Inc. Irak inhibitors and uses thereof
US9169260B2 (en) 2011-03-22 2015-10-27 Merck Sharp & Dohme Corp. Amidopyrazole inhibitors of interleukin receptor-associated kinases
NO2694640T3 (enExample) 2011-04-15 2018-03-17
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
WO2013042137A1 (en) 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
US9221809B2 (en) 2011-10-31 2015-12-29 Merck Sharp & Dohme Corp. Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
RU2658603C2 (ru) 2011-12-15 2018-06-21 Ф.Хоффманн-Ля Рош Аг Антитела против человеческого csf-1r и их применения
JP6126131B2 (ja) 2012-01-10 2017-05-10 ニンバス アイリス， インコーポレイテッド Ｉｒａｋ阻害剤およびその使用
CN104169275B (zh) 2012-01-13 2017-06-09 百时美施贵宝公司 用作激酶抑制剂的三唑取代的吡啶化合物
EP2802576B1 (en) 2012-01-13 2018-06-27 Bristol-Myers Squibb Company Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
ES2575604T3 (es) 2012-01-13 2016-06-29 Bristol-Myers Squibb Company Compuestos de piridilo sustituidos con tiazolilo o tiadiazolilo útiles como inhibidores cinasa
KR20140127855A (ko) 2012-02-06 2014-11-04 제넨테크, 인크. Csf1r 억제제를 사용하는 조성물 및 방법
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
RU2670743C9 (ru) 2012-05-11 2018-12-19 Файв Прайм Терапьютикс, Инк. Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
JP6189434B2 (ja) 2012-07-10 2017-08-30 アレス トレーディング ソシエテ アノニム ピリミジンピラゾリル誘導体
WO2014011906A2 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2014011902A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2014011911A2 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
AU2013299627C1 (en) 2012-08-09 2018-05-31 Celgene Corporation Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
WO2014058685A1 (en) 2012-10-08 2014-04-17 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
EP2903613B1 (en) 2012-10-08 2017-11-22 Merck Sharp & Dohme Corp. Pyrazole derivatives useful as inhibitors of irak4 activity
KR102233252B1 (ko) 2012-11-08 2021-03-26 브리스톨-마이어스 스큅 컴퍼니 ＩＬ-12, ＩＬ-23 및/또는 ＩＦＮα 반응의 조절제로서 유용한 알킬-아미드-치환된 피리딜 화합물
BR112015009850A2 (pt) 2012-11-08 2017-07-11 Bristol Myers Squibb Co compostos de piridila substituídos por heteroarila úteis como moduladores de quinase
HUE032863T2 (en) 2013-02-07 2017-11-28 Merck Patent Gmbh Piridazinonamid derivatives
HRP20171302T1 (hr) 2013-02-07 2017-10-20 Merck Patent Gmbh Makrociklički derivati piridazinona
US9617282B2 (en) 2013-03-15 2017-04-11 Biogen Ma Inc. Macrocyclic compounds as IRAK4 inhibitors for the treatment of inflammatory diseases
WO2014142237A1 (ja) 2013-03-15 2014-09-18 日本ゼオン株式会社 中空重合体粒子の水性分散液およびその製造方法
CN106232122A (zh) 2013-09-27 2016-12-14 林伯士艾瑞斯公司 Irak抑制剂和其用途
PT3052485T (pt) 2013-10-04 2021-10-22 Infinity Pharmaceuticals Inc Compostos heterocíclicos e suas utilizações
WO2015068856A1 (en) 2013-11-08 2015-05-14 Takeda Pharmaceutical Company Limited Pyrazole for the treatment autoimmune disorders
US10233176B2 (en) 2013-11-27 2019-03-19 Signalchem Lifesciences Corporation Aminopyridine derivatives as TAM family kinase inhibitors
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
UY35935A (es) 2014-01-03 2015-06-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4
EP3092226B1 (en) 2014-01-10 2019-03-13 Aurigene Discovery Technologies Limited Indazole compounds as irak4 inhibitors
LT3466955T (lt) 2014-01-13 2021-02-25 Aurigene Discovery Technologies Limited Oksazol[4,5-b]piridino ir tiazol[4,5-b]piridino darinių, kaip irak4 inhibitorių, skirtų vėžio gydymui, gamybos būdas
MA39749A (fr) 2014-03-17 2017-01-25 Hoffmann La Roche Dérivés de pipéridine-dione
AU2015233654B2 (en) 2014-03-19 2018-12-06 Boehringer Ingelheim International Gmbh Heteroaryl Syk inhibitors
DK3126330T3 (en) 2014-04-04 2019-04-23 Pfizer BICYCLE-FUSED HETEROARYL OR ARYL COMPOUNDS AND USE THEREOF AS IRAC4 INHIBITORS
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
US20160058872A1 (en) 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
KR20160145803A (ko) 2014-04-22 2016-12-20 님버스 아이리스 인코포레이티드 Irak 억제제 및 이의 용도
AU2015275730A1 (en) 2014-06-20 2016-12-15 Aurigene Discovery Technologies Limited Substituted indazole compounds as IRAK4 inhibitors
EP3827836A1 (en) 2014-06-27 2021-06-02 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
US10246456B2 (en) 2014-07-18 2019-04-02 Biogen Ma Inc. IRAK4 inhibiting agents
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
US9932350B2 (en) 2014-09-30 2018-04-03 Merck Sharp & Dohme Corp. Inhibitors of IRAK4 activity
EP3200790B1 (en) 2014-09-30 2020-08-26 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
EP3200788B1 (en) 2014-09-30 2019-09-18 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
US9969749B2 (en) 2014-09-30 2018-05-15 Merck Sharp & Dohme Corp. Inhibitors of IRAK4 activity
JP6787892B2 (ja) 2014-11-20 2020-11-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｉｒａｋインヒビターとしてのヘテロアリール化合物及びその使用
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2016144849A1 (en) 2015-03-12 2016-09-15 Merck Sharp & Dohme Corp. Thienopyrazine inhibitors of irak4 activity
US10155765B2 (en) 2015-03-12 2018-12-18 Merck Sharp & Dohme Corp. Carboxamide inhibitors of IRAK4 activity
WO2016144847A1 (en) 2015-03-12 2016-09-15 Merck Sharp & Dohme Corp. Pyrrolopyridazine inhibitors of irak4 activity
WO2016144848A1 (en) 2015-03-12 2016-09-15 Merck Sharp & Dohme Corp. Pyrrolotriazine inhibitors of irak4 activity
US10329294B2 (en) 2015-03-12 2019-06-25 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of IRAK4 activity
LT3286181T (lt) 2015-04-22 2021-04-26 Rigel Pharmaceuticals, Inc. Pirazolo junginiai ir junginių gamybos bei naudojimo būdas
TW201701879A (zh) 2015-04-30 2017-01-16 拜耳製藥公司 Ｉｒａｋ４抑制劑組合
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
EP3313840B1 (en) 2015-06-24 2019-07-24 Bristol-Myers Squibb Company Heteroaryl substituted aminopyridine compounds
CN105085620B (zh) 2015-06-25 2018-05-08 中山大学附属第一医院 一种靶向泛素化降解Smad3的化合物
WO2017004134A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2017004133A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2017009650A1 (en) 2015-07-14 2017-01-19 Mission Therapeutics Limited Cyanopyrrolidines as dub inhibitors for the treatment of cancer
JP2018524372A (ja) 2015-07-15 2018-08-30 アウリジーン ディスカバリー テクノロジーズ リミテッド Ｉｒａｋ−４阻害剤としてのインダゾール及びアザインダゾール化合物
CN108024971A (zh) 2015-07-15 2018-05-11 奥列基因发现技术有限公司 作为irak-4抑制剂的取代的氮杂化合物
HUE053705T2 (hu) 2015-08-27 2021-07-28 Pfizer Biciklusos kondenzált heteroaril- vagy aril- vegyületek IRAK4 modulátorokként
GB201516243D0 (en) 2015-09-14 2015-10-28 Glaxosmithkline Ip Dev Ltd Novel compounds
BR112018003812B1 (pt) 2015-09-18 2024-04-30 Merck Patent Gmbh Compostos de heteroarila como inibidores de irak, seu uso, composição farmacêutica, e kit
CN108602776B (zh) 2015-09-18 2021-12-03 默克专利有限公司 用作irak抑制剂的杂芳基化合物及其用途
EP3355922A2 (en) 2015-10-02 2018-08-08 Dana Farber Cancer Institute, Inc. Combination therapy of bromodomain inhibitors and checkpoint blockade
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
SG10202112628UA (en) 2015-11-30 2021-12-30 Anacor Pharmaceuticals Inc Topical pharmaceutical formulations for treating inflammatory-related conditions
CN108473498B (zh) 2015-12-22 2021-11-02 豪夫迈·罗氏有限公司 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物
US11427561B2 (en) 2016-01-20 2022-08-30 Biogen Ma Inc. IRAK4 inhibiting agents
WO2017201069A1 (en) 2016-05-18 2017-11-23 Biotheryx, Inc. Oxoindoline derivatives as protein function modulators
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017207385A1 (de) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Substituierte 3-methylindazole, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
GB201610147D0 (en) 2016-06-10 2016-07-27 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3475263B1 (en) 2016-06-27 2022-12-28 Rigel Pharmaceuticals, Inc. 2,4-diamino-pyrimidine compounds and their use as irak4 inhibitors
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
US11542261B2 (en) 2016-08-17 2023-01-03 Children's Hospital Medical Center Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
JP2019196309A (ja) 2016-09-15 2019-11-14 武田薬品工業株式会社 複素環化合物
WO2018064589A1 (en) 2016-09-29 2018-04-05 Dana-Farber Cancer Institute, Inc. Targeted protein degradation using a mutant e3 ubiquitin ligase
CN110506039A (zh) 2016-10-11 2019-11-26 阿尔维纳斯股份有限公司 用于雄激素受体靶向降解的化合物和方法
US10925868B2 (en) 2016-11-10 2021-02-23 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
AU2017363313B2 (en) 2016-11-22 2021-06-24 Dana-Farber Cancer Institute, Inc. Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
JP2020505327A (ja) 2016-12-23 2020-02-20 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． Ｅｇｆｒタンパク質分解標的化キメラ分子およびその関連する使用方法
BR112019015312A2 (pt) 2017-01-26 2020-03-10 Arvinas Operations, Inc. Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados
IL312367A (en) 2017-01-31 2024-06-01 Arvinas Operations Inc Cereblon ligands and bifunctional compounds comprising the same
TW202340194A (zh) 2017-02-16 2023-10-16 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
PT3621960T (pt) 2017-05-11 2021-09-16 Bristol Myers Squibb Co Tienopiridinas e benzotiofenos úteis como inibidores de irak4
PH12019502605A1 (en) 2017-05-23 2020-10-26 Theravance Biopharma R&D Ip Llc Glucuronide prodrugs of janus kinase inhibitors
JP7202315B2 (ja) 2017-05-26 2023-01-11 キャンサー・リサーチ・テクノロジー・リミテッド ベンズイミダゾロン由来のｂｃｌ６阻害剤
WO2018226542A1 (en) 2017-06-09 2018-12-13 Arvinas, Inc. Modulators of proteolysis and associated methods of use
CN110740733A (zh) 2017-06-16 2020-01-31 豪夫迈·罗氏有限公司 Irak4介导的疾患和病症的诊断和治疗方法
WO2019060742A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
WO2019075136A1 (en) 2017-10-10 2019-04-18 Aldeyra Therapeutics, Inc. TREATMENT OF INFLAMMATORY DISORDERS
WO2019094773A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
CA3085645C (en) 2017-12-13 2024-01-16 Shanghaitech University Alk protein degraders and their use in cancer therapy
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11542251B2 (en) 2018-02-14 2023-01-03 Dana-Farber Cancer Institute, Inc. IRAK degraders and uses thereof
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2020010210A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Mertk degraders and uses thereof
WO2020010177A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
CN117285467A (zh) 2018-07-31 2023-12-26 罗索肿瘤学公司 喷雾干燥的分散体和制剂
JP7297053B2 (ja) 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
JP7472103B2 (ja) 2018-08-22 2024-04-22 クルゲン（シャンハイ），インク． トロポミオシン受容体キナーゼ（ｔｒｋ）分解化合物とその使用方法
CN110862375B (zh) 2018-08-27 2022-10-25 深圳铂立健医药有限公司 吡唑化合物及其药物组合物和应用
CN112969696B (zh) 2018-11-02 2024-06-11 达纳-法伯癌症研究公司 乙酰化书写器抑制剂的开发及其用途
CA3119773A1 (en) * 2018-11-30 2020-06-04 Kymera Therapeutics, Inc. Irak degraders and uses thereof
MA54755A (fr) 2019-01-18 2021-11-24 Biogen Ma Inc Dérivés d'imidazo[1,2-a]pyridinyle servant d'inhibiteurs d'irak4
CN120574283A (zh) 2019-04-05 2025-09-02 凯麦拉医疗公司 Stat降解剂和其用途
US20230072658A1 (en) 2019-06-10 2023-03-09 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2020251974A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
WO2020251969A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
PH12022500002A1 (en) 2019-06-28 2023-04-03 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2020264490A1 (en) 2019-06-28 2020-12-30 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US20240059674A1 (en) 2019-06-28 2024-02-22 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021011634A1 (en) 2019-07-15 2021-01-21 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2021011631A1 (en) 2019-07-15 2021-01-21 Kymera Therapeutics, Inc. Fused-glutarimide crbn ligands and uses thereof
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021011871A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Mertk degraders and uses thereof
WO2021018118A1 (en) 2019-07-29 2021-02-04 Janssen Pharmaceutica Nv Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 1 proteins
WO2021053555A1 (en) 2019-09-16 2021-03-25 Novartis Ag Glue degraders and methods of use thereof
WO2021119159A1 (en) 2019-12-10 2021-06-17 Kymera Therapeutics, Inc. Irak degraders and uses thereof
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
KR20220145325A (ko) 2019-12-17 2022-10-28 카이메라 쎄라퓨틱스 인코포레이티드 Irak 분해제 및 이의 용도
US20230219945A1 (en) 2019-12-17 2023-07-13 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US20230122219A1 (en) 2020-02-03 2023-04-20 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2021168197A1 (en) 2020-02-19 2021-08-26 Nurix Therapeutics, Inc. Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof
WO2021222366A1 (en) 2020-04-28 2021-11-04 Kymera Therapeutics, Inc. Irak inhibitors and uses thereof
US20230250110A1 (en) 2020-06-03 2023-08-10 Kymera Therapeutics, Inc. Deuterated irak degraders and uses thereof
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
WO2021257914A1 (en) 2020-06-17 2021-12-23 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN116133692A (zh) 2020-07-30 2023-05-16 凯麦拉医疗公司 治疗突变淋巴瘤的方法
JP7591301B2 (ja) 2020-08-05 2024-11-28 リーディングタック ファーマシューティカル（シャオシン）カンパニー，リミテッド タンパク質を標的とし、分解するための化合物ならびにその調製方法および使用
WO2022087216A1 (en) 2020-10-21 2022-04-28 Kymera Therapeutics, Inc. Double degraders and uses thereof
US20230192655A1 (en) 2020-10-26 2023-06-22 Shanghai Leadingtac Pharmaceutical Co., Ltd. Indazole derivative, and preparation method therefor and use thereof
CN114437035A (zh) 2020-11-06 2022-05-06 海思科医药集团股份有限公司 一种抑制并降解irak4的化合物及其药物组合物和药学上的应用
IL303458A (en) 2020-12-09 2023-08-01 Kymera Therapeutics Inc IRAK joints and their uses
CN116867758A (zh) 2020-12-30 2023-10-10 凯麦拉医疗公司 Irak降解剂和其用途
WO2022161414A1 (zh) 2021-01-26 2022-08-04 成都茵创园医药科技有限公司 芳香化合物、含其的药物组合物及其应用
CN116867494A (zh) 2021-02-15 2023-10-10 凯麦拉医疗公司 Irak4降解剂和其用途
US12171768B2 (en) 2021-02-15 2024-12-24 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof
US20240383887A1 (en) 2021-05-07 2024-11-21 Kymera Therapeutics, Inc. Deuterated irak degraders and uses thereof
WO2022266258A1 (en) 2021-06-15 2022-12-22 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of irak-4
JP2024524480A (ja) 2021-07-01 2024-07-05 ハンチョウ、ヘルズン、セラピューティクス、カンパニー、リミテッド ブルトン型チロシンキナーゼ及びその突然変異体の分解剤、組成物並びにそれらの応用
EP4367113A1 (en) 2021-07-07 2024-05-15 Biogen MA Inc. Compounds for targeting degradation of irak4 proteins
US20250018046A1 (en) 2021-07-07 2025-01-16 Biogen Ma Inc Compounds for targeting degradation of irak4 proteins
CN117813307A (zh) 2021-08-18 2024-04-02 新锐思生物制药股份有限公司 白介素-1受体相关激酶的双官能降解物及其治疗用途
CA3229646A1 (en) 2021-08-23 2023-03-02 Zhengqing YE Irak4 degradation agent, and preparation method therefor and use thereof
TWI899502B (zh) 2021-09-08 2025-10-01 大陸商南京明德新藥研發有限公司 戊二醯亞胺類化合物與其應用
US20240400547A1 (en) 2021-09-26 2024-12-05 Medshine Discovery Inc. 2,6-piperidinedione compound and application thereof
CA3236265A1 (en) 2021-10-29 2023-05-04 William Leong Irak4 degraders and synthesis thereof
TW202333670A (zh) 2022-01-04 2023-09-01 大陸商海思科醫藥集團股份有限公司 抑制並降解irak4的化合物及其藥物组合物和藥學上的應用
US20230277519A1 (en) 2022-01-14 2023-09-07 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
CA3243560A1 (en) 2022-01-31 2023-08-03 Kymera Therapeutics, Inc. Iraqi Degradation Agents and Their Uses
WO2023192586A1 (en) 2022-03-31 2023-10-05 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2023186069A1 (zh) 2022-03-31 2023-10-05 石药集团中奇制药技术（石家庄）有限公司 一类白介素-1受体相关激酶4的双功能嵌合体杂环化合物及其制备方法、药用组合物和用途
AU2023253700A1 (en) 2022-04-12 2024-11-28 Genzyme Corporation Use of an irak4 modulator for gene therapy
JP2025513850A (ja) 2022-04-12 2025-04-30 ジェンザイム・コーポレーション 遺伝子治療のためのｉｒａｋ４モジュレーターの使用
CN117164583A (zh) 2022-05-20 2023-12-05 斯迈旭(苏州)生物科技有限公司 一种靶向irak4蛋白降解的化合物及其应用
AU2023282477A1 (en) 2022-06-09 2024-12-19 Beone Medicines I Gmbh Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligand and methods of use
WO2023241644A1 (zh) 2022-06-15 2023-12-21 杭州多域生物技术有限公司 一种五元并六元化合物、制备方法、药物组合物和应用
WO2024020084A1 (en) 2022-07-20 2024-01-25 Bristol-Myers Squibb Company Heteroaryl compounds as ligand directed degraders of irak4
WO2024020522A1 (en) 2022-07-22 2024-01-25 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of irak-4
CN116925085B (zh) 2022-07-23 2026-03-31 成都茵创园医药科技有限公司 Irak降解剂及其用途
CN117777126A (zh) 2022-09-29 2024-03-29 武汉人福创新药物研发中心有限公司 作为irak4降解剂的咪唑并吡啶类化合物及其用途
CN120303270A (zh) 2022-10-13 2025-07-11 凯麦拉医疗公司 Irak4降解剂的盐形式
AU2023371864A1 (en) 2022-11-04 2025-04-17 Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. Irak4 degradation agent and use thereof
AU2023398975A1 (en) 2022-12-13 2025-06-12 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
CN120641423A (zh) 2023-03-03 2025-09-12 上海齐鲁制药研究中心有限公司 Irak4降解剂及其应用
CN118946561A (zh) 2023-03-10 2024-11-12 标新生物医药科技(上海)有限公司 新颖的e3泛素连接酶配体、蛋白降解剂及其应用
CN120981450A (zh) 2023-04-03 2025-11-18 上海汇伦医药股份有限公司 靶向蛋白降解化合物及其制备方法和应用
TW202508568A (zh) 2023-04-07 2025-03-01 瑞典商阿斯特捷利康公司 Ｉｒａｋ４蛋白水解靶向嵌合體
AU2024312190A1 (en) 2023-06-23 2025-07-03 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2025024305A2 (en) 2023-07-21 2025-01-30 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
CN118047758A (zh) 2024-01-31 2024-05-17 西南交通大学 一种靶向bcl6蛋白降解的嵌合体分子及其应用
CN118440056A (zh) 2024-04-28 2024-08-06 杭州医学院 基于crbn配体诱导irak4降解的化合物及其制备方法和应用

Patent Citations (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US5602273A (en) 1982-02-01 1997-02-11 Northeastern University Release tag compounds producing ketone signal groups
US5604104A (en) 1982-02-01 1997-02-18 Northeastern University Release tag compounds producing ketone signal groups
US5610020A (en) 1982-02-01 1997-03-11 Northeastern University Release tag compounds producing ketone signal groups
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5721246A (en) 1993-09-10 1998-02-24 Eisai Co., Ltd. Heterobicyclic sulfonamide and sulfonic ester derivatives
US20020068063A1 (en) 2000-09-08 2002-06-06 Deshaies Raymond J. Proteolysis targeting chimeric pharmaceutical
WO2002020740A2 (en) 2000-09-08 2002-03-14 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
US7622496B2 (en) 2005-12-23 2009-11-24 Zealand Pharma A/S Modified lysine-mimetic compounds
US20130190340A1 (en) 2010-06-30 2013-07-25 Brandeis University Small-Molecule-Targeted Protein Degradation
WO2012003281A2 (en) 2010-06-30 2012-01-05 Brandeis University Small-molecule-targeted protein degradation
WO2012078559A2 (en) 2010-12-07 2012-06-14 Yale University Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
US20140302523A1 (en) 2010-12-07 2014-10-09 Yale University Small-Molecule Hydrophobic Tagging of Fusion Proteins and Induced Degradation of Same
US20140356322A1 (en) 2012-01-12 2014-12-04 Yale University Compounds & Methods for the Enhanced Degradation of Targeted Proteins & Other Polypeptides by an E3 Ubiquitin Ligase
WO2013106643A2 (en) 2012-01-12 2013-07-18 Yale University Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
WO2013106646A2 (en) 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
US20150225449A1 (en) 2012-09-19 2015-08-13 Hoffmann-La Roche Inc. 2-oxo-2,3,4,5-tetrahydro-1 h-benzo[b]diazepines and their use in the treatment of cancer
WO2014044622A1 (en) 2012-09-19 2014-03-27 F. Hoffmann-La Roche Ag 2-oxo-2,3,4,5-tetrahydro-1 h-benzo[b]diazepines and their use in the treatment of cancer
US20150274738A1 (en) 2012-10-19 2015-10-01 Dana-Farber Cancer, Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014063061A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014108452A1 (en) 2013-01-11 2014-07-17 Glaxosmithkline Intellectual Property Development Limited Proteolysis targeting chimeras (protacs) directed to the modulation of the estrogen receptor
WO2015071393A1 (en) 2013-11-18 2015-05-21 F. Hoffmann-La Roche Ag Tetrahydro-benzodiazepinones
US20160272596A1 (en) 2013-11-18 2016-09-22 Hoffmann-La Roche Ag Tetrahydro-benzodiazepinones
US20150291562A1 (en) 2014-04-14 2015-10-15 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2015160845A2 (en) 2014-04-14 2015-10-22 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
US20160022642A1 (en) 2014-07-25 2016-01-28 Yale University Compounds Useful for Promoting Protein Degradation and Methods Using Same
US20180009779A1 (en) 2014-12-23 2018-01-11 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2016105518A1 (en) 2014-12-23 2016-06-30 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US20160214972A1 (en) 2015-01-20 2016-07-28 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2016118666A1 (en) 2015-01-20 2016-07-28 Arvinas, Inc. Compounds and methods for the targeted degradation of the androgen receptor
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
US20160272639A1 (en) 2015-03-18 2016-09-22 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
WO2016149668A1 (en) 2015-03-18 2016-09-22 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
WO2016169989A1 (en) 2015-04-22 2016-10-27 Glaxosmithkline Intellectual Property Development Limited Iap e3 ligase directed proteolysis targeting chimeric molecules
US20180118733A1 (en) 2015-04-22 2018-05-03 Glaxosmithkline Intellectual Property Development Limited lAP E3 LIGASE DIRECTED PROTEOLYSIS TARGETING CHIMERIC MOLECULES
WO2016197032A1 (en) 2015-06-04 2016-12-08 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2016197114A1 (en) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
US20180147202A1 (en) 2015-06-05 2018-05-31 Arvinas, Inc. TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US20180134684A1 (en) 2015-07-07 2018-05-17 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017011371A1 (en) 2015-07-10 2017-01-19 Arvinas, Inc Mdm2-based modulators of proteolysis and associated methods of use
US20170008904A1 (en) 2015-07-10 2017-01-12 Arvinas, Inc. Mdm2-based modulators of proteolysis and associated methods of use
US20170037004A1 (en) 2015-07-13 2017-02-09 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
WO2017011590A1 (en) 2015-07-13 2017-01-19 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
US20170121321A1 (en) 2015-11-02 2017-05-04 Yale University Proteolysis Targeting Chimera Compounds and Methods of Preparing and Using Same
WO2017079267A1 (en) 2015-11-02 2017-05-11 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
WO2017108744A1 (de) 2015-12-22 2017-06-29 Bayer Pharma Aktiengesellschaft Neue substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2017117473A1 (en) 2015-12-30 2017-07-06 Dana-Farber Cancer Institute, Inc. Bifunctional molescules for her3 degradation and methods of use
WO2017117474A1 (en) 2015-12-30 2017-07-06 Dana-Farber Cancer Institute, Inc. Bifunctional compounds for her3 degradation and methods of use
WO2017148902A1 (de) 2016-03-03 2017-09-08 Bayer Pharma Aktiengesellschaft Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
US20190071432A1 (en) 2016-03-03 2019-03-07 Bayer Pharma Aktiengesellschaft New 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
WO2017161119A1 (en) 2016-03-16 2017-09-21 H. Lee Moffitt Cancer Center & Research Institute, Inc. Small molecules against cereblon to enhance effector t cell function
US20170281784A1 (en) 2016-04-05 2017-10-05 Arvinas, Inc. Protein-protein interaction inducing technology
WO2017176708A1 (en) 2016-04-05 2017-10-12 Arvinas, Inc. Protein-protein interaction inducing technology
WO2017176958A1 (en) 2016-04-06 2017-10-12 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
WO2017176957A1 (en) 2016-04-06 2017-10-12 The Regents Of The University Of Michigan Mdm2 protein degraders
US20190076542A1 (en) 2016-05-10 2019-03-14 C4 Theraprutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
US20190076540A1 (en) 2016-05-10 2019-03-14 C4 Theraprutics, Inc. Spirocyclic degronimers for target protein degradation
US20190076541A1 (en) 2016-05-10 2019-03-14 C4 Theraprutics, Inc. Heterocyclic degronimers for target protein degradation
US20190076539A1 (en) 2016-05-10 2019-03-14 C4 Theraprutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
WO2018134684A1 (zh) 2017-01-18 2018-07-26 阿尔卡特朗讯 无线接入网中用于网络切片的资源分配方法和编排器
WO2018237026A1 (en) 2017-06-20 2018-12-27 C4 Therapeutics, Inc. N / O-LINKED DEGRONS AND DEGRONIMERS FOR DEGRADATION OF PROTEINS
WO2019043214A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag glutarimide
WO2019084026A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
WO2019099868A2 (en) 2017-11-16 2019-05-23 C4 Therapeutics, Inc. Degraders and degrons for targeted protein degradation
WO2019099926A1 (en) * 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
WO2019165229A1 (en) 2018-02-23 2019-08-29 Dana-Farber Cancer Institute, Inc. Small molecules for inducing selective protein degradation and uses thereof
WO2019236483A1 (en) 2018-06-04 2019-12-12 C4 Therapeutics, Inc. Spirocyclic compounds
WO2020018788A1 (en) 2018-07-20 2020-01-23 Dana-Farber Cancer Institute, Inc. Degraders that target proteins via keap1

Non-Patent Citations (24)

* Cited by examiner, † Cited by third party
Title
"Handbook of Chemistry and Physics", article "Periodic Table of the Elements"
"March's Advanced Organic Chemistry", 2001, JOHN WILEY & SONS
BEMDSEN ET AL.: "New insights into ubiquitin E3 ligase mechanism", NAT. STRUCT. MOL. BIOL., vol. 21, 2014, pages 301 - 307, XP055420625, DOI: 10.1038/nsmb.2780
CREWS C, CHEMISTRY & BIOLOGY, vol. 17, no. 6, 2010, pages 551 - 555
DESHAIES ET AL.: "RING domain E3 ubiquitin ligases", ANN. REV. BIOCHEM., vol. 78, 2009, pages 399 - 434, XP055005600, DOI: 10.1146/annurev.biochem.78.101807.093809
HINES, J ET AL., CANCER RES
LI ET AL.: "Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle's dynamics and signaling", PLOS ONE, vol. 3, 2008, pages 1487
LU ET AL., EURO. J. MED. CHEM., vol. 146, 2018, pages 251 - 9
M. TOUREC. M. CREWS, ANGEW. CHEM. INT. ED., vol. 55, 2016, pages 1966
ROSTOVTSEV ET AL., ANGEW. CHEM., vol. 41, 2002, pages 2596 - 99
S. M. BERGE ET AL., J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19
SCHNNEKLOTH JS JR., CHEMBIOCHEM, vol. 6, no. 1, 2005, pages 40 - 46
See also references of EP3989966A4
SHANMUGASUNDARAM, K ET AL., J. BIO. CHEM., 2019
SPRADIN, J.N. ET AL., BIORXIV (DOI: HTTPS://DOI.ORG/10.1101/436998
SPRATT ET AL.: "RBR E3 ubiquitin ligases: new structures, new insights, new questions", BIOCHEM., vol. 458, 2014, pages 421 - 437
SUN ET AL., BIOCONJUGATE CHEM., vol. 17, 2006, pages 52 - 57
T. UEHARA ET AL., NATURE CHEMICAL BIOLOGY, vol. 13, 2017, pages 675
THOMAS SORRELL: "Organic Chemistry", 1999, UNIVERSITY SCIENCE BOOKS
TONG ET AL.: "Targeted Protein Degradation via a Covalent Reversible Degrader Based on Bardoxolone", CHEMRXIV, 2020
VARFOLOMEEV, E ET AL.: "IAP Antagonists Induce Autoubiquitination of c-IAPs, NF- B activation, and TNFa-Dependent Apoptosis", CELL, vol. 131, no. 4, 2007, pages 669 - 81, XP055048525, DOI: 10.1016/j.cell.2007.10.030
WANG ET AL.: "Roles of F-box proteins in cancer", NAT. REV. CANCER., vol. 14, 2014, pages 233 - 347
WARD, C.C. ET AL., BIORXIV (DOI: HTTPS://DOI.C RG/10.1101/439125
ZHANG, X ET AL., BIORXIV (DOI: HTTPS://DOI.ORG/10.1101/443804

Cited By (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12410193B2 (en) 2014-01-13 2025-09-09 Aurigene Oncology Limited Bicyclic heterocyclyl derivatives as IRAK4 inhibitors
US12168057B2 (en) 2017-12-26 2024-12-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11318205B1 (en) 2017-12-26 2022-05-03 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11723980B2 (en) 2017-12-26 2023-08-15 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US12516068B2 (en) 2018-01-12 2026-01-06 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11807636B2 (en) 2018-11-30 2023-11-07 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US12258341B2 (en) 2018-11-30 2025-03-25 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11352350B2 (en) 2018-11-30 2022-06-07 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US12077555B2 (en) 2019-04-05 2024-09-03 Kymera Therapeutics, Inc. STAT degraders and uses thereof
US11746120B2 (en) 2019-04-05 2023-09-05 Kymera Therapeutics, Inc. Stat degraders and uses thereof
US12545659B2 (en) 2019-06-28 2026-02-10 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US12558427B2 (en) 2019-07-17 2026-02-24 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US12551564B2 (en) 2019-12-10 2026-02-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US12539295B2 (en) 2019-12-17 2026-02-03 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
EP4076520A4 (en) * 2019-12-17 2024-03-27 Kymera Therapeutics, Inc. IRAQ DEGRADATION AGENTS AND THEIR USES
US11707457B2 (en) 2019-12-17 2023-07-25 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11779578B2 (en) 2019-12-17 2023-10-10 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11685750B2 (en) 2020-06-03 2023-06-27 Kymera Therapeutics, Inc. Crystalline forms of IRAK degraders
US11857535B2 (en) 2020-07-30 2024-01-02 Kymera Therapeutics, Inc. Methods of treating mutant lymphomas
WO2022088551A1 (zh) * 2020-10-26 2022-05-05 上海领泰生物医药科技有限公司 吲唑类衍生物及其制备方法和应用
US12150995B2 (en) 2020-12-30 2024-11-26 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2022161414A1 (zh) * 2021-01-26 2022-08-04 成都茵创园医药科技有限公司 芳香化合物、含其的药物组合物及其应用
CN112724079A (zh) * 2021-02-04 2021-04-30 康化（上海）新药研发有限公司 一种6-甲氧基吡啶甲酸甲酯的合成方法
US12171768B2 (en) 2021-02-15 2024-12-24 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof
US12497402B2 (en) 2021-02-15 2025-12-16 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof
CN117279893A (zh) * 2021-03-01 2023-12-22 奥仁公司 用于制备cyp11a1抑制剂及其中间体的方法
WO2022184975A1 (en) * 2021-03-01 2022-09-09 Orion Corporation Process for the preparation of a cyp11a1 inhibitor and intermediates thereof
US20220331330A1 (en) * 2021-04-08 2022-10-20 Curis, Inc. Combination therapies for the treatment of cancer
US12178821B2 (en) * 2021-04-08 2024-12-31 Curis, Inc. Combination therapies for the treatment of cancer
US12097261B2 (en) 2021-05-07 2024-09-24 Kymera Therapeutics, Inc. CDK2 degraders and uses thereof
EP4333836A4 (en) * 2021-05-07 2025-07-23 Kymera Therapeutics Inc DEUTERATED IRAQ DEGRADING AGENTS AND THEIR USES
JP2024517340A (ja) * 2021-05-14 2024-04-19 アプリノイア セラピューティクス リミテッド アルファ－シヌクレイン凝集物を分解する化合物及びその使用
CN117440956A (zh) * 2021-06-11 2024-01-23 帝斯曼知识产权资产管理有限公司 用于生产生物素中间体的工艺
CN117440956B (zh) * 2021-06-11 2026-03-17 帝斯曼知识产权资产管理有限公司 用于生产生物素中间体的工艺
EP4352065A4 (en) * 2021-06-11 2025-03-12 DSM IP Assets B.V. METHOD FOR PRODUCING A BIOTIN INTERMEDIATE
WO2022257152A1 (en) * 2021-06-11 2022-12-15 Dsm Ip Assets B.V. Process for producing biotin intermediate
WO2022266258A1 (en) * 2021-06-15 2022-12-22 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of irak-4
JP2024527570A (ja) * 2021-07-07 2024-07-25 バイオジェン・エムエイ・インコーポレイテッド Ｉｒａｋ４タンパク質の分解をターゲティングするための化合物
JP2024525580A (ja) * 2021-07-07 2024-07-12 バイオジェン・エムエイ・インコーポレイテッド Ｉｒａｋ４タンパク質の分解をターゲティングするための化合物
WO2023283372A1 (en) * 2021-07-07 2023-01-12 Biogen Ma Inc. Compounds for targeting degradation of irak4 proteins
WO2023021081A1 (en) * 2021-08-20 2023-02-23 Henkel Ag & Co. Kgaa Vinyl ethers
WO2023025159A1 (zh) * 2021-08-23 2023-03-02 上海领泰生物医药科技有限公司 Irak4降解剂及其制备方法和应用
JP2024536872A (ja) * 2021-09-26 2024-10-08 メッドシャイン ディスカバリー インコーポレイテッド ２，６－ピペリジンジオン系化合物とその使用
JP7806223B2 (ja) 2021-09-26 2026-01-26 ▲ザン▼州片仔▲ファン▼薬業股▲フン▼有限公司 ２，６－ピペリジンジオン系化合物とその使用
WO2023045978A1 (zh) * 2021-09-26 2023-03-30 南京明德新药研发有限公司 2,6-哌啶二酮类化合物与其应用
US12187744B2 (en) 2021-10-29 2025-01-07 Kymera Therapeutics, Inc. IRAK4 degraders and synthesis thereof
US20250122192A1 (en) * 2021-12-03 2025-04-17 Rgenta Therapeutics, Inc. 5-pyrimidinecarboxamide derivatives and methods of using the same
US20240294502A1 (en) * 2021-12-23 2024-09-05 Hangzhou Polymed Biopharmaceuticals, Inc. Five-membered-fused six-membered compound, preparation method, pharmaceutical composition and use
WO2023116920A1 (zh) * 2021-12-23 2023-06-29 杭州多域生物技术有限公司 一种五元并六元化合物、制备方法、药物组合物和应用
US12195479B2 (en) 2021-12-23 2025-01-14 Hangzhou Polymed Biopharmaceuticals, Inc. Five- and six-membered compound, and preparation method therefor and pharmaceutical composition and use thereof
WO2023116866A1 (zh) * 2021-12-23 2023-06-29 杭州多域生物技术有限公司 一种五元并六元化合物、制备方法、药物组合物和应用
US12281098B2 (en) * 2021-12-23 2025-04-22 Hangzhou Polymed Biopharmaceuticals, Inc. Five-membered-fused six-membered compound, preparation method, pharmaceutical composition and use
WO2023131167A1 (zh) 2022-01-04 2023-07-13 海思科医药集团股份有限公司 一种抑制并降解irak4的化合物及其药物组合物和药学上的应用
WO2023143249A1 (zh) * 2022-01-28 2023-08-03 上海齐鲁制药研究中心有限公司 靶向malt1的蛋白降解化合物
US12091411B2 (en) 2022-01-31 2024-09-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2023178323A1 (en) * 2022-03-18 2023-09-21 Henry Ford Health System Therapeutic inhibition of cd38 to treat hidradenitis suppurativa
WO2024020522A1 (en) * 2022-07-22 2024-01-25 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of irak-4
WO2024126617A1 (en) 2022-12-14 2024-06-20 Crossfire Oncology Holding B.V. Bifunctional compounds for degrading kinases via ubiquitin proteosome pathway
WO2024199147A1 (zh) * 2023-03-24 2024-10-03 漳州片仔癀药业股份有限公司 2,6-哌啶二酮类化合物的晶型、制备方法及其应用
WO2024199135A1 (zh) * 2023-03-24 2024-10-03 漳州片仔癀药业股份有限公司 2,6-哌啶二酮类化合物盐型和晶型的制备方法及其应用
WO2024209044A1 (en) 2023-04-07 2024-10-10 Astrazeneca Ab Irak4 protacs
WO2024245331A1 (zh) 2023-05-30 2024-12-05 上海汇伦医药股份有限公司 三并环类化合物、其制备方法和应用
EP4620470A3 (en) * 2023-06-23 2025-10-08 Kymera Therapeutics, Inc. Irak degraders and uses thereof
WO2025003987A1 (ko) * 2023-06-29 2025-01-02 동화약품주식회사 신규한 카르복사마이드 유도체 화합물 및 이를 포함하는 약학적 조성물
WO2025010326A3 (en) * 2023-07-03 2025-03-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Dimeric immuno-modulatory compounds against cereblon-based mechanisms
WO2025011655A1 (zh) 2023-07-13 2025-01-16 成都茵创园医药科技有限公司 芳香化合物、含其的药物组合物及其应用
WO2025036285A1 (zh) 2023-08-11 2025-02-20 深圳众格生物科技有限公司 一种降解irak4的蛋白降解靶向嵌合体化合物及其应用
WO2025061203A1 (zh) * 2023-09-21 2025-03-27 成都茵创园医药科技有限公司 Irak降解剂及其用途
WO2025126115A1 (en) 2023-12-13 2025-06-19 Beigene Switzerland Gmbh Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligands and methods of use
WO2025125575A1 (en) * 2023-12-14 2025-06-19 Astrazeneca Ab Irak4 protacs
WO2025221154A1 (en) * 2024-04-17 2025-10-23 Captor Therapeutics S.A. Klhdc2 (kelch domain-containing protein 2) ligase ligands
WO2026061418A1 (en) * 2024-09-18 2026-03-26 Beone Pharmaceutical (Suzhou) Co., Ltd. Dual irak1/irak4 degraders, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
JP2025113407A (ja) 2025-08-01
KR20220032063A (ko) 2022-03-15
PH12022500002A1 (en) 2023-04-03
MX2021015995A (es) 2022-03-11
EP3989966A1 (en) 2022-05-04
US20230069104A1 (en) 2023-03-02
MX2024013970A (es) 2024-12-06
JP7687970B2 (ja) 2025-06-03
IL289267A (en) 2022-02-01
BR112021026517A2 (pt) 2022-05-10
US12545659B2 (en) 2026-02-10
AU2020302118A1 (en) 2022-02-24
US20260042749A1 (en) 2026-02-12
EP3989966A4 (en) 2023-09-27
CA3144805A1 (en) 2020-12-30
CN114502158A (zh) 2022-05-13
CO2021017893A2 (es) 2022-01-17
JP2022538192A (ja) 2022-08-31

Similar Documents

Publication Publication Date Title
JP7687970B2 (ja) Ｉｒａｋ分解剤およびその使用
US11779578B2 (en) IRAK degraders and uses thereof
JP7623943B2 (ja) Ｉｒａｋ分解剤およびそれらの使用
AU2021413371A9 (en) Irak degraders and uses thereof
US20230089916A1 (en) Irak degraders and uses thereof
US20230234953A1 (en) Irak degraders and uses thereof
WO2020251971A1 (en) Smarca degraders and uses thereof
WO2021158634A1 (en) Irak degraders and uses thereof
EP4472967A2 (en) Irak degraders and uses thereof
WO2019133531A1 (en) Irak degraders and uses thereof
US20250375526A1 (en) Irak degraders and uses thereof
WO2022125804A1 (en) Smarca degraders and uses thereof
WO2023049790A2 (en) Mdm2 degraders and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20833679

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3144805

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021577410

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: NC2021/0017893

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021026517

Country of ref document: BR

WWP Wipo information: published in national office

Ref document number: NC2021/0017893

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: DZP2022000045

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 20227003218

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2021137823

Country of ref document: RU

Ref document number: 2020833679

Country of ref document: EP

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112021026517

Country of ref document: BR

Free format text: APRESENTAR A TRADUCAO SIMPLES DA FOLHA DE ROSTO DA CERTIDAO DE DEPOSITO E DA CESSAO DE TODAS AS PRIORIDADES REIVINDICADAS OU DECLARACAO CONTENDO, OBRIGATORIAMENTE, TODOS OS DADOS IDENTIFICADORES DESTAS CONFORME O ART. 15 DA PORTARIA 39/2021. O DOCUMENTO APRESENTADO NAO ESTA TRADUZIDO.

ENP Entry into the national phase

Ref document number: 2020302118

Country of ref document: AU

Date of ref document: 20200629

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112021026517

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20211227

WWE Wipo information: entry into national phase

Ref document number: 523441373

Country of ref document: SA

WWR Wipo information: refused in national office

Ref document number: 521431222

Country of ref document: SA

WWE Wipo information: entry into national phase

Ref document number: 521431222

Country of ref document: SA

WWE Wipo information: entry into national phase

Ref document number: 521431222

Country of ref document: SA

WWD Wipo information: divisional of initial pct application

Ref document number: 822872

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 521431222

Country of ref document: SA

WWG Wipo information: grant in national office

Ref document number: 202117061095

Country of ref document: IN

WWG Wipo information: grant in national office

Ref document number: 17597165

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 289267

Country of ref document: IL